var title_f7_4_7232="Rapid rise in blood pressure after discontinuation of chronic antihypertensive therapy";
var content_f7_4_7232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Rapid rise in blood pressure after discontinuation of chronic antihypertensive therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 422px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a trial performed by the Medical Research Council Working Party of Mild Hypertension, 2765 patients were randomly assigned to bendrofluazide, propranolol, or placebo. Both systolic and diastolic pressures fell more with drug therapy than placebo (phase 1). At six years, patients in the drug therapy groups were reassigned to continued therapy or placebo (phase 2). The fall in both systolic and diastolic pressures was maintained in those on continued therapy, while switching to placebo led, within nine to twelve months, to a rise in blood pressure to a level similar to the values in patients treated with placebo from the beginning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Medical Research Council Working Party of Mild Hypertension, Br Med J 1986; 293:988.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7232=[""].join("\n");
var outline_f7_4_7232=null;
var title_f7_4_7233="Patient information: Intraventricular hemorrhage in newborns (The Basics)";
var content_f7_4_7233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Intraventricular hemorrhage in newborns (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/intraventricular-hemorrhage-in-newborns-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7554911\">",
"      <span class=\"h1\">",
"       What is intraventricular hemorrhage in newborns?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Intraventricular hemorrhage in newborns is a condition that happens when blood vessels inside a newborn baby&rsquo;s brain burst and bleed. It is most common in newborns who:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Are born more than 8 weeks early (this is called &ldquo;preterm&rdquo; or &ldquo;premature&rdquo; birth). A normal pregnancy lasts 40 weeks, so babies born at 32 weeks or less are more likely to have this problem.",
"       </li>",
"       <li>",
"        Newborns who weigh about 3 pounds or less. This is less than half the weight of an average newborn.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7554926\">",
"      <span class=\"h1\">",
"       What are the symptoms of intraventricular hemorrhage in newborns?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some newborns have no symptoms. A baby that has symptoms might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Be more sleepy or less alert than usual",
"       </li>",
"       <li>",
"        Have weak, floppy muscles",
"       </li>",
"       <li>",
"        Move less than normal",
"       </li>",
"       <li>",
"        Stop breathing for short periods of time",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7554940\">",
"      <span class=\"h1\">",
"       Is there a test for intraventricular hemorrhage in newborns?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can test for this condition with an ultrasound of the baby&rsquo;s head. An ultrasound uses sound waves to create pictures of the inside of the body. Some doctors do routine ultrasounds on premature babies to check for this condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7554955\">",
"      <span class=\"h1\">",
"       How is intraventricular hemorrhage in newborns treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are no treatments to stop the bleeding. But your baby&rsquo;s doctor will check to make sure your baby&rsquo;s blood flow and oxygen levels are normal. This can prevent further bleeding.",
"     </p>",
"     <p>",
"      Your baby might need fluids given through a small tube in a vein, called an &ldquo;IV.&rdquo; He or she might also need oxygen, which is given through:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A plastic hood put over the baby&rsquo;s head",
"       </li>",
"       <li>",
"        2 plastic tubes put in the baby&rsquo;s nostrils",
"       </li>",
"       <li>",
"        A mask over the baby&rsquo;s mouth and nose in a treatment called &ldquo;continuous positive airway pressure&rdquo; or CPAP.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7554970\">",
"      <span class=\"h1\">",
"       Can intraventricular hemorrhage in newborns be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce the chance that your baby will have an intraventricular hemorrhage by going to all your doctor or midwife&rsquo;s visits when you are pregnant and following their advice. This will lower the chances that you will have a baby that is born too early.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/4/7233?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83999 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-7D7969DF47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7233=[""].join("\n");
var outline_f7_4_7233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7554911\">",
"      What is intraventricular hemorrhage in newborns?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7554926\">",
"      What are the symptoms of intraventricular hemorrhage in newborns?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7554940\">",
"      Is there a test for intraventricular hemorrhage in newborns?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7554955\">",
"      How is intraventricular hemorrhage in newborns treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7554970\">",
"      Can intraventricular hemorrhage in newborns be prevented?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_4_7234="Salter IV fracture";
var content_f7_4_7234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salter IV fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP view of the right foot. Salter Harris type IV fracture of the proximal phalanx of the first toe with associated soft tissue swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Mathison, MD and Dewesh Agrawal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7234=[""].join("\n");
var outline_f7_4_7234=null;
var title_f7_4_7235="Infectious colitis Doppler US";
var content_f7_4_7235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infectious colitis on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal ultrasonography in a patient with infectious colitis. Color Doppler imaging, reveals hypervascularity especially of the submucosa. The bowel wall is thickened (10 mm). Microbiological examination confirmed salmonella infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7235=[""].join("\n");
var outline_f7_4_7235=null;
var title_f7_4_7236="Mometasone (nasal): Patient drug information";
var content_f7_4_7236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mometasone (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/23/38261?source=see_link\">",
"     see \"Mometasone (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/20/42307?source=see_link\">",
"     see \"Mometasone (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8775137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nasonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8775138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nasonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose irritation. It may take 2 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose polyps.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mometasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3682982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray up the nose only. Do not spray onto the wall joining your two nostrils.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store spray at room temperature. Throw away any part not used after labeled number of doses are used.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12255 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7236=[""].join("\n");
var outline_f7_4_7236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775137\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024314\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024313\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024318\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024319\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024321\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024316\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024317\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024322\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024323\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/23/38261?source=related_link\">",
"      Mometasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/20/42307?source=related_link\">",
"      Mometasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/11/34998?source=related_link\">",
"      Mometasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7654?source=related_link\">",
"      Mometasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/6/28773?source=related_link\">",
"      Mometasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=related_link\">",
"      Mometasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/61/13268?source=related_link\">",
"      Mometasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/8/13444?source=related_link\">",
"      Mometasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_4_7237="M mode cardiomyopathy II";
var content_f7_4_7237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of cardiomyopathy compared to normal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal M-modes of the minor axis of the left ventricle are taken along the line (Mp) superimposed on the anatomical diagram in panel A. Panel B is from a normal patient and panel C is from a patient with cardiomyopathy. The minor axis dimension of the normal left ventricle (LV) at the end of systole (LVESd) is 5.2 cm compared to 6.3 cm in the patient with cardiomyopathy; the LV end diastolic dimensions (LVEDd) are 3.4 and 5.3 cm, respectively. The fractional shortening of the normal heart (LVEDd - LVESd /LVEDd) is 35 percent) is compared to 16 percent for that of the heart with cardiomyopathy. Panels D and E are M-mode echocardiograms obtained from a level nearer to the LV base and the beam is passed through the mitral valve. In the normal heart (panel D) the mitral valve (MV) opens widely, very near to the septum (S); in the cardiomyopathic heart MV opening is reduced, due to a low stroke volume ,and it is separated from the septum by nearly 2 cm; this separation is called E point mitral-septal separation, or EPSS.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; IVS: interventricular septum; PM: papillary muscle; PML: posterior mitral valve leafet; AML: anterior mitral valve leaflet; Ao: aorta; LVW: left ventricular posterior wall.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7237=[""].join("\n");
var outline_f7_4_7237=null;
var title_f7_4_7238="Exemestane: Drug information";
var content_f7_4_7238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Exemestane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/30/485?source=see_link\">",
"    see \"Exemestane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aromasin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aromasin&reg;;",
"     </li>",
"     <li>",
"      CO Exemestane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Aromatase Inactivator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Postmenopausal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, advanced:",
"     </b>",
"     Oral: 25 mg once daily; continue until tumor progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, early (adjuvant treatment):",
"     </b>",
"     Oral: 25 mg once daily (following 2-3 years of tamoxifen therapy) for a total duration of 5 years of endocrine therapy (in the absence of recurrence or contralateral breast cancer)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, risk reduction (unlabeled use):",
"     </b>",
"     Oral: 25 mg once daily for up to 5 years (Goss, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with CYP3A4 inducers:",
"     </b>",
"     U.S. labeling: 50 mg once daily when used with potent inducers (eg, rifampin, phenytoin)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary (although the safety of chronic doses in patients with moderate-to-severe renal impairment has not been studied, dosage adjustment does not appear necessary).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F169511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary (although the safety of chronic doses in patients with  moderate-to-severe hepatic impairment has not been studied, dosage adjustment does not appear necessary).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aromasin&reg;: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1954090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy; adjuvant treatment of postmenopausal estrogen receptor-positive early breast cancer following 2-3 years of tamoxifen (for a total of 5 years of adjuvant therapy)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13359903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Risk reduction for invasive breast cancer in postmenopausal women; treatment of endometrial cancer; treatment of uterine sarcoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4091418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aromasin&reg; may be confused with Arimidex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Exemestane may be confused with estramustine.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (8% to 22%), insomnia (11% to 14%), pain (13%),  headache (7% to 13%), depression (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatological: Hyperhidrosis (4% to 18%), alopecia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (13% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9% to 18%), abdominal pain (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (14% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (15% to 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (6% to 7%); cardiac ischemic events (2%: MI, angina, myocardial ischemia); chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8% to 10%), anxiety (4% to 10%), fever (5%), confusion, hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (8%), itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic:  Weight gain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4% to 10%), vomiting (7%), anorexia (6%), constipation (5%),  appetite increased (3%), dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (9%), limb pain (9%), myalgia (6%), osteoarthritis (6%), weakness (6%), osteoporosis (5%), pathological fracture (4%), paresthesia (3%), carpal tunnel syndrome (2%), cramps (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (10%), cough (6%), bronchitis, pharyngitis, rhinitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (6%), lymphedema, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Cardiac failure, cholestatic hepatitis, endometrial hyperplasia, gastric ulcer, GGT increased, hepatitis, hypersensitivity, neuropathy, osteochondrosis, pruritus, thromboembolism, transaminases increased, trigger finger, urticaria, uterine polyps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     A dose-dependent decrease in sex hormone-binding globulin has been observed with daily doses of &ge;2.5 mg. Serum luteinizing hormone and follicle-stimulating hormone levels have increased with this medicine.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to exemestane or any component of the formulation; use in women who are or may become pregnant; use in premenopausal women",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Due to decreased circulating estrogen levels, exemestane is associated with a reduction in bone mineral density. Decreases (from baseline) in lumbar spine and femoral neck density have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lymphopenia: Grade 3 or 4 lymphopenia has been observed with exemestane use, although most patients had preexisting lower grade lymphopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lab parameters: Increases in bilirubin, alkaline phosphatase and serum creatinine have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inducers: Dose adjustment recommended with concomitant CYP3A4 inducers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Estrogen-containing drugs: Should not be administered concurrently with estrogen-containing drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin D deficiency: Due to high prevalence of vitamin D deficiency in women with breast cancer, assess 25-hydroxy vitamin D levels at baseline and supplement accordingly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F169518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Exemestane. Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Plasma levels increased by 40% when exemestane was taken with a fatty meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease exemestane levels. Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Not indicated for use in premenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1943700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take after a meal; patients on aromatase inhibitor therapy should receive vitamin D and calcium supplements.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F169491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aromasin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $565.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Exemestane Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $392.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16249401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     25-hydroxy vitamin D levels (at baseline); bone mineral density",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F169493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aromasil (ES);",
"     </li>",
"     <li>",
"      Aromasin (AE, AR, AU, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, EC, EE, EG, FI, GB, GT, HK, HN, ID, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LY, MY, NI, NL, NO, OM, PA, PE, PH, PL, PT, QA, SA, SE, SG, SV, SY, TH, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Aromasine (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exemestane is an irreversible, steroidal aromatase inactivator. It is structurally related to androstenedione, and is converted  to an intermediate that irreversibly blocks the active site of the aromatase enzyme, leading to inactivation (&ldquo;suicide inhibition&rdquo;) and thus preventing conversion of androgens to estrogens in peripheral tissues. In postmenopausal breast cancers where growth is estrogen-dependent, this medicine will lower circulating estrogens.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and moderate (~42%) following oral administration; absorption increases ~40% following high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive into tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%, primarily to albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; oxidation (CYP3A4) of methylene group, reduction of 17-keto group with formation of many secondary metabolites; metabolites are inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Women with breast cancer: 1.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as unchanged drug, 39% to 45% as metabolites); feces (36% to 48%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, Campone M, Piccart M, et al, &ldquo;Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(6):520-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/22149876/pubmed\" id=\"22149876\" target=\"_blank\">",
"        22149876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bertelli G, Hall E, Ireland E, et al, &ldquo;Long-Term Endometrial Effects in Postmenopausal Women With Early Breast Cancer Participating in the Intergroup Exemestane Study (IES) -- A Randomised Controlled Trial of Exemestane versus Continued Tamoxifen After 2-3 Years Tamoxifen,\"",
"      <i>",
"       Ann Oncol,",
"      </i>",
"      2010, 21(3):498-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/19717534/pubmed\" id=\"19717534\" target=\"_blank\">",
"        19717534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burstein HJ, Prestrud AA, Seidenfeld J, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(23):3784-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/20625130/pubmed\" id=\"20625130\" target=\"_blank\">",
"        20625130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buzdar AU, Robertson JF, Eiermann W, et al, &ldquo;An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(9):2006-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/12404296/pubmed\" id=\"12404296\" target=\"_blank\">",
"        12404296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chia S, Gradishar W, Mauriac L, et al, &ldquo;Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(10):1664-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/18316794/pubmed\" id=\"18316794\" target=\"_blank\">",
"        18316794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goss PE, Ingle JN, Ales-Martinez JE, et al, &ldquo;Exemestane for Breast-Cancer Prevention in Postmenopausal Women,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(25):2381-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/21639806/pubmed\" id=\"21639806\" target=\"_blank\">",
"        21639806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kieback DG, Harbeck N, Bauer W, et al, &ldquo;Endometrial Effects of Exemestane Compared to Tamoxifen Within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) Trial: Results of a Prospective Gynecological Ultrasound Substudy,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2010, 119(3):500-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/20832103/pubmed\" id=\"20832103\" target=\"_blank\">",
"        20832103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lonning PE, &ldquo;Pharmacological Profiles of Exemestane and Fromestane, Steroidal Aromatase Inhibitors Used for Treatment of Postmenopausal Breast Cancer,&rdquo;",
"      <i>",
"       Breast Cancer Res Treat",
"      </i>",
"      , 1998, 49(Suppl 1):45-52.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morandi P, Rouzier R, Altundag K, et al, &ldquo;The Role of Aromatase Inhibitors in the Adjuvant Treatment of Breast Carcinoma: The M. D. Anderson Cancer Center Evidence-Based Approach,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(7):1482-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/15378476/pubmed\" id=\"15378476\" target=\"_blank\">",
"        15378476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 2.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paridaens RJ, Dirix LY, Beex LV, et al, &ldquo;Phase III Study Comparing Exemestane With Tamoxifen as First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(30):4883-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/18794551/pubmed\" id=\"18794551\" target=\"_blank\">",
"        18794551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Njar VC and Brodie AM, &ldquo;Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1999, 58(2):233-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/10473018/pubmed\" id=\"10473018\" target=\"_blank\">",
"        10473018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winer EP, Hudis C, Burstein HJ, et al, \"American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(3):619-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/4/7238/abstract-text/15545664/pubmed\" id=\"15545664\" target=\"_blank\">",
"        15545664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8920 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7238=[""].join("\n");
var outline_f7_4_7238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169505\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169506\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169523\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169508\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169509\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169510\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169511\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169484\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169470\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1954090\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169485\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13359903\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4091418\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169521\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169489\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169474\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169518\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169479\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169501\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169481\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169492\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169514\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1943700\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169491\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16249401\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169493\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169473\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169488\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/30/485?source=related_link\">",
"      Exemestane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_4_7239="Paraneoplastic visual syndromes";
var content_f7_4_7239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraneoplastic visual syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7239/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7239/contributors\">",
"     Josep Dalmau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7239/contributors\">",
"     Myrna R Rosenfeld, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7239/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7239/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/4/7239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2791602\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. In most cases, their pathogenesis is believed to be immune-mediated.",
"   </p>",
"   <p>",
"    Paraneoplastic visual syndromes are rare; they include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and paraneoplastic optic neuropathy (optic neuritis).",
"   </p>",
"   <p>",
"    This topic discusses paraneoplastic visual syndromes. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2792544\">",
"    <span class=\"h1\">",
"     CANCER-ASSOCIATED RETINOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer-associated retinopathy (CAR), while rare, is probably the most common of the paraneoplastic visual syndromes. The pathogenesis of CAR is believed to be a B-cell mediated autoimmune response directed against an antigen expressed by both tumor and retina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/1\">",
"     1",
"    </a>",
"    ]. T-cell responses may also play a role.",
"   </p>",
"   <p>",
"    Although at least 20 antigens have been described in the CAR syndrome, the most commonly associated is recoverin, a calcium-binding protein involved in transduction of light by photoreceptors (",
"    <a class=\"graphic graphic_picture graphicRef67930 \" href=\"UTD.htm?8/35/8754\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Recoverin is expressed in the tumors of patients with lung cancer with or without CAR; antibodies to CAR may occur in patients without visual symptoms, although the titres are relatively low compared to patients with visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Anti-recoverin antibodies have been shown to induce apoptotic death of photoreceptor cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/6\">",
"     6",
"    </a>",
"    ]. Anti-enolase antibodies are associated with a less severe retinopathy that affects mainly the cones; not all patients with anti-enolase associated retinopathy have cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Other antigens have been identified in patients with CAR; some patients with CAR are seronegative suggesting that other antigens remain to be characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histopathology reveals diffuse loss of inner and outer segments of the photoreceptors and loss of the outer nuclear layer with preservation of the inner nuclear layer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/13\">",
"     13",
"    </a>",
"    ]. Inflammation is variably observed.",
"   </p>",
"   <p>",
"    Patients with CAR develop symptoms related to dysfunction of both cones (ie, photosensitivity, abnormal visual acuity, color vision abnormalities, central scotomata) and rods (ie, nyctalopia or night blindness, prolonged dark adaptation, peripheral or ring-like scotomata). Patients typically describe photopsias along with bilateral visual dimming that progresses over days to weeks. The triad of photosensitivity, ring scotomatous visual field loss, and attenuated retinal arteriole caliber is strongly suggestive of this disorder, although the optic fundus can appear normal in the early stages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/14\">",
"     14",
"    </a>",
"    ]. Optic disc pallor and mottling of the epithelium develop in later stages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroretinogram (ERG) is abnormal, with depressed a and b-waves in both photopic and scotopic conditions, reflecting damage to both rods and cones. Cerebrospinal fluid analysis may be normal or show mild lymphocytic pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated protein.",
"   </p>",
"   <p>",
"    Small cell lung cancer (SCLC) is the most commonly associated tumor; CAR has been described with other lung cancers, as well as gynecologic cancers and less frequently, breast cancer, lymphoma, hepatocellular carcinoma, colon cancer, prostate cancer, and thymoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/13,15-20\">",
"     13,15-20",
"    </a>",
"    ]. CAR precedes cancer diagnosis in approximately half of patients.",
"   </p>",
"   <p>",
"    Patients with unexplained vision loss with clinical or electrophysiologic evidence of rod and cone dysfunction or known or suspected malignancy should be evaluated for CAR. Testing should include measurement of anti-retinal antibodies along with investigation for underlying neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Occult malignancy'",
"    </a>",
"    .) Negative antibody titres on initial examination, can become positive on subsequent testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/21\">",
"     21",
"    </a>",
"    ]. The specificity of anti-recoverin antibodies for underlying neoplasm in patients with retinopathy appears to be high; in one series, all 12 patients with retinopathy and anti-recoverin antibodies had cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/22\">",
"     22",
"    </a>",
"    ]. In another series of 521 patients with a diagnosis of retinitis pigmentosa, ten patients had antirecoverin antibody",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular immunoreactivity; none of these patients appeared to have systemic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/23\">",
"     23",
"    </a>",
"    ]. Anti-enolase and other antibodies are not specific for CAR and may be seen in patients with noncancer-related autoimmune retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditionally, CAR has been treated with corticosteroids with anecdotal reports of mild to moderate improvement that was often unsustained [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. Treatment of the underlying tumor also does not clearly affect visual prognosis. There are anecdotal, uncontrolled reports of a treatment response to intravenous immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/25\">",
"     25",
"    </a>",
"    ], plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/26\">",
"     26",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/19\">",
"     19",
"    </a>",
"    ]. For most patients, however, the visual prognosis is poor with progressive visual loss and eventual blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2792551\">",
"    <span class=\"h1\">",
"     MELANOMA-ASSOCIATED RETINOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sera of patients with melanoma-associated retinopathy (MAR) contain antibodies that react with the bipolar cells of the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Potential antigens (eg, arrestin, transducin) have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Anti-retinal antibodies are also prevalent (in as many as 69 percent) in patients with melanoma but no retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/34\">",
"     34",
"    </a>",
"    ]. In one series, 9 of 11 patients with MAR had a family or personal history of autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features of melanoma-associated retinopathy (MAR) include shimmering, flickering, or pulsating photopsias, night blindness, and loss of peripheral vision [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/28,35-37\">",
"     28,35-37",
"    </a>",
"    ]. Color vision is preserved. The onset is usually acute and may begin in one eye. Vision loss progresses slowly; in one series, visual acuity was",
"    <span class=\"nowrap\">",
"     20/60",
"    </span>",
"    or better in more than 80 percent of patients at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Funduscopic examination is usually normal at onset, with retinal arterial attenuation seen later [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/13,37\">",
"     13,37",
"    </a>",
"    ]. Vitreous cells are seen in a few patients. The electroretinogram shows a characteristic pattern of a markedly reduced b-wave in the presence of a normal, dark-adapted a-wave, consistent with bipolar and Muller cell dysfunction. Cerebrospinal fluid analysis is generally normal.",
"   </p>",
"   <p>",
"    MAR usually presents in the setting of known melanoma diagnosis sometimes after an interval of months to years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/37\">",
"     37",
"    </a>",
"    ]. MAR may precede the diagnosis of melanoma. Patients with any form of melanoma (cutaneous, choroidal, ciliary body, or choroidal nevi) may be affected, usually in the context of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. A few patients with a MAR-like illness have been reported in patients with colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of MRA is usually made in the setting of a typical clinical presentation in a patient with melanoma. Western blot and immunohistological examination can demonstrate anti-retinal antibodies but this has imperfect sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vision loss typically stabilizes or progresses slowly. Some patients, but not most, improve with treatment of the tumor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with immunotherapy: glucocorticoids, plasma exchange,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous immune globulin (IVIG) (eg, 0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    daily for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/12,15,27,37-39\">",
"     12,15,27,37-39",
"    </a>",
"    ]; there are no controlled studies. Some believe that MAR is associated with prolonged survival from melanoma, but this has not been rigorously assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791281\">",
"    <span class=\"h1\">",
"     OPTIC NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic optic neuritis (PON) has been described in a few reports, usually in association with other paraneoplastic neurologic syndromes, in particular encephalomyelitis or retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. Many of these patients harbor antibodies to the 62kDa collapsin-responsive mediator protein-5 (CRMP-5, also called anti-CV2) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/42-44,46\">",
"     42-44,46",
"    </a>",
"    ]. However, the small number of patients, the extensive number of accompanying symptoms, and the frequent co-occurrence of other antibodies suggest low specificity and sensitivity of CRMP-5 antibodies as markers of paraneoplastic optic neuritis or retinitis associated with SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present with painless visual loss and optic disc edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/13,43,47\">",
"     13,43,47",
"    </a>",
"    ]. Both eyes are usually ultimately involved. MRI reveals a swollen optic nerve that may mildly enhance.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    angiography can show optic disc hyperfluorescence and leakage. Vitreous cells may be prominent. Cerebrospinal fluid may reveal a mild lymphocytic pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mildly elevated protein. Neuropathologic findings demonstrate findings consistent with optic neuritis including perivascular lymphocytic infiltration and demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43,47\">",
"     43,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to encephalomyelitis and retinitis, other associated paraneoplastic syndromes occurring with PON include cerebellar ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43,46,48-50\">",
"     43,46,48-50",
"    </a>",
"    ], a Devic-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and ophthalmoplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/41,51\">",
"     41,51",
"    </a>",
"    ]. Optic nerve dysfunction can precede, accompany, or occur after other neurologic symptoms. Some patients are described with isolated PON [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43,47,52-55\">",
"     43,47,52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PON usually occurs in the setting of known cancer, but occasionally is its first manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/15\">",
"     15",
"    </a>",
"    ]. Small cell lung cancer (SCLC) is the most commonly associated cancer, but PON along with anti CRMP-5 antibodies are described in non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/52\">",
"     52",
"    </a>",
"    ], thymoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/44\">",
"     44",
"    </a>",
"    ], renal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43\">",
"     43",
"    </a>",
"    ] and thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vision may improve with anti-tumor treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/15,27,46\">",
"     15,27,46",
"    </a>",
"    ]. In some reports, systemic corticosteroids are also associated with improvement, but this is not invariable; associated neurologic symptoms appear less likely to respond to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/27,45,53,54\">",
"     27,45,53,54",
"    </a>",
"    ]. One report describes visual improvement in two cases with intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4052000\">",
"    <span class=\"h1\">",
"     BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral diffuse uveal melanocytic proliferation (BDUMP) describes a syndrome in which vision loss occurs along with diffuse bilateral proliferation of melanocytes in the uveal tract in patients with cancer. The mechanism is unknown, but does not appear to be mediated by autoimmunity.",
"   </p>",
"   <p>",
"    Patients present with vision loss of varying severity, with normal acuity to light perception only [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Visual symptoms often precede cancer diagnosis; associated malignancies include ovarian, uterine, lung, and pancreatic cancers. Funduscopic examination is often normal at first presentation, but later may reveal multiple, subtle, round or oval, red patches.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    angiography reveals multifocal hyperfluorescence corresponding with these patches. Diffuse thickening of the uveal tract with elevated focal tumors may also be seen. Optical coherence tomography reveals loss of the retinal pigment epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral retinal detachments and rapid cataract formation follow. These respond poorly if at all to surgical therapy, and most patients become blind. In limited reports, corticosteroid treatment does not appear to impact outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/58,63\">",
"     58,63",
"    </a>",
"    ]. Patients with BDUMP treated with irradiation for presumed choroidal metastases had worsened vision [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/13\">",
"     13",
"    </a>",
"    ]. However, one case report describes improved vision in a women treated with external beam irradiation supplemented by drainage of subretinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the melanocytes are believed to be benign, there is one described case of a patient with ovarian carcinoma and BDUMP who subsequently developed metastatic malignant amelanotic melanoma to the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/57\">",
"     57",
"    </a>",
"    ]. BDUMP is associated with poor survival, mean 12 to 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7239/abstract/13,57\">",
"     13,57",
"    </a>",
"    ]. Death usually results from complications of the underlying malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791288\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic visual syndromes include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and paraneoplastic optic neuropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CAR develop photosensitivity, abnormal visual acuity, color vision abnormalities, and central or ring-like scotomata. Small cell lung cancer (SCLC) and gynecologic tumors are the most commonly associated tumors. (See",
"      <a class=\"local\" href=\"#H2792544\">",
"       'Cancer-associated retinopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of MAR include shimmering, flickering, or pulsating photopsias, night blindness, and loss of peripheral vision. MAR may precede the diagnosis of melanoma. (See",
"      <a class=\"local\" href=\"#H2792551\">",
"       'Melanoma-associated retinopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of CAR and MAR is usually ineffective, however, some patients improve with treatment of the tumor or immunotherapy (See",
"      <a class=\"local\" href=\"#H2792544\">",
"       'Cancer-associated retinopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2792551\">",
"       'Melanoma-associated retinopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paraneoplastic optic neuritis has been described in a few reports, usually in association with paraneoplastic encephalomyelitis or retinitis and SCLC. (See",
"      <a class=\"local\" href=\"#H2791281\">",
"       'Optic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilateral diffuse uveal melanocyte proliferation describes a rare paraneoplastic syndrome. This has a poor prognosis with bilateral retinal detachment and rapid cataract formation leading to blindness in many patients. Survival is shortened as well, with death resulting from complications of the underlying malignancy. (See",
"      <a class=\"local\" href=\"#H4052000\">",
"       'Bilateral diffuse uveal melanocytic proliferation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/1\">",
"      Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002; 514:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/2\">",
"      Thirkill CE, FitzGerald P, Sergott RC, et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 1989; 321:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/3\">",
"      Polans AS, Burton MD, Haley TL, et al. Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/4\">",
"      Polans AS, Witkowska D, Haley TL, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci U S A 1995; 92:9176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/5\">",
"      Bazhin AV, Shifrina ON, Savchenko MS, et al. Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision. Lung Cancer 2001; 34:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/6\">",
"      Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 2002; 132:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/7\">",
"      Weleber RG, Watzke RC, Shults WT, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 2005; 139:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/8\">",
"      Adamus G, Aptsiauri N, Guy J, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 1996; 78:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/9\">",
"      Dot C, Guigay J, Adamus G. Anti-alpha-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung. Am J Ophthalmol 2005; 139:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/10\">",
"      Magrys A, Anekonda T, Ren G, Adamus G. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol 2007; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/11\">",
"      Eichen JG, Dalmau J, Demopoulos A, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol 2001; 21:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/12\">",
"      Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 2009; 8:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/13\">",
"      Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/14\">",
"      Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990; 28:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/15\">",
"      Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol 2003; 48:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/16\">",
"      Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 2001; 131:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/17\">",
"      Katsuta H, Okada M, Nakauchi T, et al. Cancer-associated retinopathy associated with invasive thymoma. Am J Ophthalmol 2002; 134:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/18\">",
"      Yamada G, Ohguro H, Aketa K, et al. Invasive thymoma with paraneoplastic retinopathy. Hum Pathol 2003; 34:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/19\">",
"      Espandar L, O'Brien S, Thirkill C, et al. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol 2007; 83:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/20\">",
"      Chang PY, Yang CH, Yang CM, Yang CM. Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review. Retina 2005; 25:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/21\">",
"      Ohguro H, Yokoi Y, Ohguro I, et al. Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 2004; 137:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/22\">",
"      Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/23\">",
"      Heckenlively JR, Fawzi AA, Oversier J, et al. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol 2000; 118:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/24\">",
"      Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 1992; 110:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/25\">",
"      Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 1999; 117:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/26\">",
"      Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol 1997; 17:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/27\">",
"      Damek DM. Paraneoplastic Retinopathy/Optic Neuropathy. Curr Treat Options Neurol 2005; 7:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/28\">",
"      Boeck K, Hofmann S, Klopfer M, et al. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol 1997; 137:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/29\">",
"      Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/30\">",
"      Potter MJ, Adamus G, Szabo SM, et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol 2002; 134:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/31\">",
"      Bazhin AV, Dalke C, Willner N, et al. Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer 2009; 124:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/32\">",
"      Hartmann TB, Bazhin AV, Schadendorf D, Eichm&uuml;ller SB. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer 2005; 114:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/33\">",
"      Pf&ouml;hler C, Preuss KD, Tilgen W, et al. Mitofilin and titin as target antigens in melanoma-associated retinopathy. Int J Cancer 2007; 120:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/34\">",
"      Ladewig G, Reinhold U, Thirkill CE, et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol 2005; 152:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/35\">",
"      Lu Y, Jia L, He S, et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol 2009; 127:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/36\">",
"      Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988; 106:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/37\">",
"      Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/38\">",
"      Subhadra C, Dudek AZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 2008; 28:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/39\">",
"      Jacobzone C, Cochard-Marianowski C, Kupfer I, et al. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol 2004; 140:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/40\">",
"      Chan C, O'Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 2001; 29:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/41\">",
"      Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and \"optic neuritis\": paraneoplastic effects of bronchial carcinoma. Neurology 1984; 34:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/42\">",
"      Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/43\">",
"      Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/44\">",
"      Ducray F, Roos-Weil R, Garcia PY, et al. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007; 78:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/45\">",
"      Moss HE, Liu GT, Dalmau J. Glazed (vision) and confused. Surv Ophthalmol 2010; 55:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/46\">",
"      de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/47\">",
"      Sheorajpanday R, Slabbynck H, Van De Sompel W, et al. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol 2006; 26:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/48\">",
"      Thambisetty MR, Scherzer CR, Yu Z, et al. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol 2001; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/49\">",
"      Malik S, Furlan AJ, Sweeney PJ, et al. Optic neuropathy: a rare paraneoplastic syndrome. J Clin Neuroophthalmol 1992; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/50\">",
"      Luiz JE, Lee AG, Keltner JL, et al. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol 1998; 18:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/51\">",
"      Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol 1988; 45:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/52\">",
"      Pulido J, Cross SA, Lennon VA, et al. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond) 2008; 22:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/53\">",
"      Ar&eacute;s-Luque A, Garc&iacute;a-Tu&ntilde;&oacute;n LA, Saiz A, et al. Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol 2007; 254:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/54\">",
"      Murakami Y, Yoshida S, Yoshikawa H, et al. CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinoma. Eye (Lond) 2007; 21:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/55\">",
"      Asproudis IC, Nikas AN, Psilas KG. Paraneoplastic optic neuropathy in a patient with a non-small cell lung carcinoma: a case report. Eur J Ophthalmol 2005; 15:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/56\">",
"      O'Neal KD, Butnor KJ, Perkinson KR, Proia AD. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol 2003; 48:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/57\">",
"      Duong HV, McLean IW, Beahm DE. Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol 2006; 142:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/58\">",
"      Saito W, Kase S, Yoshida K, et al. Bilateral diffuse uveal melanocytic proliferation in a patient with cancer-associated retinopathy. Am J Ophthalmol 2005; 140:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/59\">",
"      Ritland JS, Eide N, Tausj&oslash; J. Bilateral diffuse uveal melanocytic proliferation and uterine cancer. A case report. Acta Ophthalmol Scand 2000; 78:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/60\">",
"      Kiratli H, Erkan K. Loss of Retinal Pigment Epithelium Associated with Bilateral Diffuse Uveal Melanocytic Proliferation. Ophthalmic Surg Lasers Imaging 2010; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/61\">",
"      Besirli CG, Comer GM. High-resolution OCT imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging 2010; 41 Suppl:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/62\">",
"      Wu S, Slakter JS, Shields JA, Spaide RF. Cancer-associated nummular loss of the pigment epithelium. Am J Ophthalmol 2005; 139:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7239/abstract/63\">",
"      Sen J, Clewes AR, Quah SA, et al. Presymptomatic diagnosis of bronchogenic carcinoma associated with bilateral diffuse uveal melanocytic proliferation. Clin Experiment Ophthalmol 2006; 34:156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15837 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7239=[""].join("\n");
var outline_f7_4_7239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2791288\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2791602\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2792544\">",
"      CANCER-ASSOCIATED RETINOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2792551\">",
"      MELANOMA-ASSOCIATED RETINOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2791281\">",
"      OPTIC NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4052000\">",
"      BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2791288\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/15837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15837|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/35/8754\" title=\"picture 1\">",
"      Recoverin and photoreceptors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_4_7240="Kaposi sarcoma on TBBx";
var content_f7_4_7240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transbronchial biopsy specimen shows proliferation of spindle cells with associated hemorrhagic features that is characteristic of Kaposi sarcoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7240=[""].join("\n");
var outline_f7_4_7240=null;
var title_f7_4_7241="Exercise capacity and VO2 in heart failure";
var content_f7_4_7241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise capacity and VO2 in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7241/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7241/contributors\">",
"     Ileana L Pi&ntilde;a, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7241/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7241/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/4/7241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitation of exercise capacity is one of the cardinal manifestations of heart failure (HF), varying directly with the severity of the disease. Thus, decreased maximal exercise capacity is associated with decreased patient survival. Exercise training may have a variety of benefits, including an improvement in quality of life, reduced hospitalization, and improved survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The methods used to measure exercise capacity, the factors that limit exercise capacity in HF, and the use of measurement of peak exercise capacity (also called functional exercise testing) to predict prognosis will be reviewed here. The recommendations generally adhere to those published in 2000 by the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/1\">",
"     1",
"    </a>",
"    ]. The beneficial effects of exercise training in patients with HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF EXERCISE CAPACITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peak exercise capacity is defined as \"the maximum ability of the cardiovascular system to deliver oxygen to exercising skeletal muscle and of the exercising muscle to extract oxygen from the blood\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, exercise tolerance is determined by three factors: pulmonary gas exchange; cardiovascular performance, including the peripheral vascular tree; and skeletal muscle metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Peak VO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise capacity can be quantitated clinically by measurement of oxygen uptake (VO2), carbon dioxide production (VCO2), and minute ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/3\">",
"     3",
"    </a>",
"    ]. These parameters are measured during exercise with rapidly responding gas analyzers capable of breath-by-breath determination of O2 and CO2 concentrations in inspired and expired air, respectively. The maximal oxygen uptake (V02max) eventually reaches a plateau despite increasing workload (",
"    <a class=\"graphic graphic_figure graphicRef62094 \" href=\"UTD.htm?29/41/30366\">",
"     figure 1",
"    </a>",
"    ). Not surprisingly, VO2max has a strong linear correlation with both cardiac output and skeletal muscle blood flow (",
"    <a class=\"graphic graphic_figure graphicRef65079 \" href=\"UTD.htm?7/45/7902\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    .) The peak VO2 divided by the heart rate",
"    <span class=\"nowrap\">",
"     (peakVO2/HR)",
"    </span>",
"    is called the oxygen pulse and is an indirect measure of stroke volume.",
"   </p>",
"   <p>",
"    The relationship between cardiac output and O2 uptake (or oxygen consumption) also forms the basis for the Fick equation used to measure cardiac output:",
"   </p>",
"   <p>",
"    &nbsp;Cardiac output &nbsp; = &nbsp; O2 uptake (VO2) &nbsp;&divide; &nbsp;Arteriovenous O2 difference (A-V O2)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ventilatory threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ventilatory threshold (VT), formerly referred to as the anaerobic threshold (AT), is another index used to estimate exercise capacity. It is defined as the point at which minute ventilation increases disproportionately relative to VO2, a response that is generally seen at 60 to 70 percent of VO2max (",
"    <a class=\"graphic graphic_figure graphicRef62094 \" href=\"UTD.htm?29/41/30366\">",
"     figure 1",
"    </a>",
"    ). The VT is a reflection of the disproportionate increase in lactic acid production by working muscles. It can be used to distinguish between noncardiac (pulmonary or musculoskeletal) and cardiac causes of exercise limitation, since patients who fatigue prior to reaching VT are likely to have a noncardiac problem [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Six-minute walk test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six-minute walk test is useful, simple, and inexpensive test that correlates with VO2max and outcomes has been used in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This submaximal exercise test measures the distance ambulated on a level hallway surface during six minutes as described in the 2002",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/resources/pfet/sixminute.pdf\">",
"     American Thoracic Society (ATS) statement on the six-minute walk test.",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXERCISE CAPACITY IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise capacity is reduced even in mild heart failure. The cardiac output may be relatively normal at rest, but is usually unable to increase adequately with even mild exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/4\">",
"     4",
"    </a>",
"    ]. As in normal subjects, peak VO2 in HF is directly related to peak exercise cardiac output and muscle blood flow (",
"    <a class=\"graphic graphic_figure graphicRef65079 \" href=\"UTD.htm?7/45/7902\">",
"     figure 2",
"    </a>",
"    ). However, the inability to appropriately increase cardiac output results in an insufficient increase in perfusion to exercising muscle, which can cause early anaerobic metabolism, muscle fatigue, and eventual muscle wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/9\">",
"     9",
"    </a>",
"    ]. Since HF patients often do not attain a true VO2 max, the term \"peak VO2\" is often used.",
"   </p>",
"   <p>",
"    Several factors, in addition to myocardial dysfunction, may contribute to the inadequate response to exercise in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inotropic and chronotropic response to catecholamines is reduced; this defect is due at least in part to downregulation of &szlig;-receptors in the presence of chronically elevated circulating catecholamine levels [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"       \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Augmentation of stroke volume via the Starling mechanism may be limited by diastolic dysfunction (changes in the",
"      <span class=\"nowrap\">",
"       pressure/volume",
"      </span>",
"      curve) or pericardial constraint.",
"     </li>",
"     <li>",
"      In contrast to normals, exercise is associated with an elevation in the pulmonary wedge pressure. This can exacerbate pulmonary congestion, thereby causing dyspnea and limiting exercise capacity. The high left-sided pressure is accompanied by equalization with right atrial pressure, probably due to pericardial constraint in addition to increased blood return to the right side of the heart.",
"     </li>",
"     <li>",
"      The presence of pulmonary hypertension and increased pulmonary vascular resistance can reduce the cardiac output response to exercise, impairing exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concurrent mitral regurgitation may be present, limiting the increase in forward output when the regurgitation becomes severe.",
"     </li>",
"     <li>",
"      Both biochemical and functional abnormalities in skeletal muscle are often present, limiting muscle metabolic capacity (",
"      <a class=\"graphic graphic_figure graphicRef54643 \" href=\"UTD.htm?29/58/30638\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"       \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced respiratory muscle endurance may be present as part of the generalized skeletal myopathy in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/14\">",
"     14",
"    </a>",
"    ]. This abnormality may contribute to the symptoms of fatigue and dyspnea on exertion.",
"   </p>",
"   <p>",
"    The diaphragm shows a different adaptation from skeletal and respiratory muscle. There is a shift from fast to slow fibers with an increase in oxidative capacity and a decrease in glycolytic capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/15\">",
"     15",
"    </a>",
"    ]. These changes are similar to those seen in the limb muscles that occur with endurance training, suggesting that they result from the increased work of breathing.",
"   </p>",
"   <p>",
"    There are also changes in pulmonary function in HF. Even in the absence of pulmonary congestion, HF is associated with impaired pulmonary diffusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/16\">",
"     16",
"    </a>",
"    ] and an exaggerated increase in minute ventilation in response to exercise, out of proportion to the increase in carbon dioxide production [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Hyperventilation is primarily due to",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    mismatching, the severity of which is related to the severity of the heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/18\">",
"     18",
"    </a>",
"    ]. The combination of increased ventilation and normal gas exchange (unless limited by pulmonary congestion) means that arterial hypoxia does not generally occur during exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PEAK VO2 AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32497339\">",
"    <span class=\"h2\">",
"     Predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak VO2 (maximal oxygen consumption) provides the most objective assessment of functional capacity in patients with heart failure. This parameter is a surrogate marker for the maximal cardiac output that an individual can achieve. Patients with a peak VO2 &le;10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min have the worst prognosis (normal value with exercise is above 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min) (",
"    <a class=\"graphic graphic_figure graphicRef63516 \" href=\"UTD.htm?20/38/21101\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The predictive value of peak VO2 is valid only in patients whose exercise capacity is limited by heart failure. In patients with other limiting comorbidities, additional or alternative exercise parameters may be helpful.",
"   </p>",
"   <p>",
"    In addition, since peak VO2 is influenced by age, gender, and body weight, the percent predicted value may be a more reliable indicator of prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Values of 50 percent or more are associated with an excellent short-term prognosis.",
"   </p>",
"   <p>",
"    The peak VO2 is an important component in the evaluation of patients for cardiac transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential utility of percent predicted peak VO2 was illustrated in a study of exercise testing in 181 ambulatory patients with CHF who were being considered for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/20\">",
"     20",
"    </a>",
"    ]. Survival in patients who achieved &le;50 percent predicted VO2max was significantly lower than in those who achieved more than 50 percent predicted VO2max at one (74 versus 98 percent) and two years (43 versus 90 percent). Use of the percent predicted VO2max provided additional prognostic information to the absolute peak VO2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of peak VO2 has several limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The data correlating peak VO2 and outcomes were derived before the use of therapies that improve survival in patients with advanced HF, such as beta blockers. With such therapies, peak VO2 still predicts survival but a peak VO2 cut point lower than 14",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min may be warranted as an indication for referral for transplantation. However, peak VO2 must be considered in the setting of the patient&rsquo;s age and gender, given that age is the most powerful predictor of peak VO2 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link&amp;anchor=H8#H8\">",
"       \"Indications and contraindications for cardiac transplantation\", section on 'Peak VO2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The predictive value of peak VO2 is accurate only when exercise capacity is limited by heart failure. Factors that can prematurely terminate the test must be excluded, including significant peripheral muscular deconditioning, peripheral artery disease, arthritis, angina pectoris, or low patient motivation. In such situations, patients are unable to achieve VO2max. The proper interpretation of the peak VO2 requires that the patient achieve the ventilatory threshold (VT), indicating that the level of exercise performed exceeded that which can be supported by the cardiovascular system on an aerobic basis.",
"     </li>",
"     <li>",
"      Peak VO2 may be less useful in women than in men. The influence of gender on both peak VO2 and its prognostic value was illustrated in a series of 594 patients with advanced HF (28 percent women) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/22\">",
"       22",
"      </a>",
"      ]. Although women were younger (49 versus 53 years in men) and had better systolic function (mean LVEF 29 versus 25 percent), the mean peak VO2 was lower in women than in men (14.0 versus 16.6 percent, respectively). Despite the lower peak VO2, women had a higher one-year transplant-free survival (94 versus 81 percent). A better measure of exercise capacity in women may be the percent predicted peak VO2 for age and body weight. In the HF-ACTION trial, the peak VO2 for women did correlate with NYHA Class but was considerably lower than that for the men [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absolute peak VO2 is also influenced by such factors as age and body weight. The percent predicted peak VO2 corrects for these factors and may be a more accurate determinant of prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Heart failure centers have been using the percent predicted peak VO2 to assess prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Additional predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of peak VO2 may be enhanced by additional measures of the physiologic response to exercise:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic blood pressure &mdash; The predictive value of peak exercise systolic blood pressure was illustrated in a three year follow-up study of 500 patients with HF referred for transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/24\">",
"       24",
"      </a>",
"      ]. On multivariate analysis, peak exercise systolic blood pressure and the percent predicted VO2max were the two most important predictors for the combined end point of death or listing for transplant. The three-year survival rate for patients with a peak exercise VO2 &le;14",
"      <span class=\"nowrap\">",
"       ml/min/kg",
"      </span>",
"      who were unable to reach a peak exercise systolic blood pressure of 120 mmHg was 55 percent compared to 83 percent for those able to achieve this blood pressure (",
"      <a class=\"graphic graphic_figure graphicRef70524 \" href=\"UTD.htm?41/10/42157\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cardiac output &mdash; The incremental predictive survival value of the cardiac output response to maximal exercise was illustrated in the following studies:",
"      <br/>",
"      <br/>",
"      In a study 185 patients with advanced heart failure, a \"normal\" cardiac output response to exercise provided incremental information above the absolute VO2 determination in predicting survival [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/25\">",
"       25",
"      </a>",
"      ]. This was especially true in patients with VO2max responses below 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min.",
"      <br/>",
"      219 patients who underwent exercise testing while being monitored with a Swan-Ganz catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/26\">",
"       26",
"      </a>",
"      ]. Peak exercise stroke work index was the most powerful prognostic variable; the two year survival for those with a stroke work index &le;30",
"      <span class=\"nowrap\">",
"       gm/m2",
"      </span>",
"      was 54 percent compared with 91 percent for those with an index &gt;30",
"      <span class=\"nowrap\">",
"       gm/m2",
"      </span>",
"      (p &lt;0.0001). Among patients with a relatively low peak VO2, those who had a normal cardiac output response to exercise had an excellent two year survival (87 versus 58 percent in the others) (",
"      <a class=\"graphic graphic_figure graphicRef71980 \" href=\"UTD.htm?27/12/27853\">",
"       figure 6",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      However, invasive hemodynamic exercise determinations are not practical for routine evaluation. Furthermore, a smaller study found that only 6 percent of patients had a normal response to exercise, suggesting that this approach may not be cost-effective [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ventilatory threshold &mdash; It has been suggested that the VT might be more predictive than the peak VO2 because it is less prone to error. In one report of 223 consecutive patients with heart failure, a VT &lt;11",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min was more predictive of six month mortality than a peak VO2 &le;14",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min (odds ratio 5.3 versus 3.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/28\">",
"       28",
"      </a>",
"      ]. The risk is almost doubled when a low VT was combined with impaired ventilatory efficiency (odds ratio 9.6).",
"     </li>",
"     <li>",
"      Stress induced LV dilation &mdash; One noninvasive technique that may be helpful, particularly in patients with an idiopathic dilated cardiomyopathy who have a borderline VO2max (10 to 14",
"      <span class=\"nowrap\">",
"       ml/kg/min)",
"      </span>",
"      is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography. An increase in left ventricular end-diastolic diameter and wall stress in such patients is predictive of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32496427\">",
"    <span class=\"h1\">",
"     OTHER PREDICTIVE EXERCISE PARAMETERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32497388\">",
"    <span class=\"h2\">",
"     Six-minute walk test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six-minute walk test may distinguish better between Class III and IV and may correlate less well with peak VO2 for Class I and II.",
"   </p>",
"   <p>",
"    The predictive value of the six-minute walk distance is illustrated by the following studies. In a retrospective analysis of 440 patients from a randomized controlled trial with NYHA class III or IV HF, baseline distance significantly predicted mortality and hospitalization; for each 100 m increase in distance walked, the hazard ratio was 0.58 and 0.85, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/7\">",
"     7",
"    </a>",
"    ]. Similarly, in a series of 476 patients from a single referral center, the distance walked at baseline was an independent predictor of two-year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between six-minute walk distance and health status is also important for identifying clinically meaningful changes. In HF-ACTION, changes in patient-reported health status by the Kansas City Cardiomyopathy Questionnaire (KCCQ) were weakly correlated with changes in functional capacity. A 5 point improvement in KCCQ was associated with a 112 m improvement in six-minute walk distance and a 2.5",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    increase in peak VO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32496488\">",
"    <span class=\"h2\">",
"     Exercise duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HF ACTION, the most powerful predictor of the primary endpoint (death or all cause hospitalization) or death at median 2.5 year follow-up was exercise duration on a standardized baseline cardiopulmonary exercise test (Modified Naughton protocol) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32496435\">",
"    <span class=\"h2\">",
"     Ventilatory efficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible alternative in patients who cannot achieve VO2max is measurement of the ventilatory efficiency, ie, ventilation-to-carbon dioxide production ratio in early exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. During cardiopulmonary exercise testing, a close linear relationship exists between the production of CO2 (VCO2) and minute ventilation (VE). The slope of the regression line relating CO2 production and minute ventilation",
"    <span class=\"nowrap\">",
"     (VE/VCO2)",
"    </span>",
"    can be used to describe the ventilatory response to exercise. In patients with heart failure, the",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    slope is easier to obtain than parameters of maximal exercise capacity and is a better predictor of outcome than VO2max, NYHA class, or left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/28,34,35\">",
"     28,34,35",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Heart failure is associated with an increase in VE due to increased dead space ventilation because of poor",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    matching, and an increase in VCO2 relative to VO2 resulting from bicarbonate buffering of lactic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/36\">",
"     36",
"    </a>",
"    ]. A",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    regression line slope of &gt;34 is associated with reduced cardiac output during exercise, increased pulmonary artery wedge pressures, and reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/28,32\">",
"     28,32",
"    </a>",
"    ]. In one report, patients with a",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    slope above 34 had more severe heart failure with significantly reduced survival during 18 month follow-up (69 versus 95 percent for those with lower values) (",
"    <a class=\"graphic graphic_figure graphicRef59902 \" href=\"UTD.htm?37/18/38189\">",
"     figure 7",
"    </a>",
"    ). In addition, an elevated",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    slope adds incremental prognostic value to both VO2max [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/32,34\">",
"     32,34",
"    </a>",
"    ] and the anaerobic threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/28\">",
"     28",
"    </a>",
"    ], while a value above 44.7 adds incremental prognostic value to a low chronotropic index, which correlates with the peak heart rate achieved with exercise (",
"    <a class=\"graphic graphic_figure graphicRef66454 \" href=\"UTD.htm?3/16/3342\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    An increase in",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    slope is also predictive of outcome in patients with preserved exercise capacity. Among 123 patients with a VO2max &ge;18",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute, the three year survival was significantly lower in those with a",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    &ge;34 (57 versus 93 percent for",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    &le;34) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32496471\">",
"    <span class=\"h2\">",
"     Oxygen uptake efficiency parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxygen uptake efficiency slope (OUES) is a parameter derived from VO2 and minute ventilation (VE) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/39\">",
"     39",
"    </a>",
"    ]. This parameter appears insensitive to the duration of exercise and correlates with outcomes in patients with advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/40\">",
"     40",
"    </a>",
"    ]. These features suggest that OUES may be more useful than peak VO2, particularly in patients with limited exercise capacity for reasons other than HF.",
"   </p>",
"   <p>",
"    A preliminary study of 508 patients with HF with left ventricular ejection fraction &lt;35 percent found that the highest plateau of oxygen uptake efficiency (OUEP) during incremental cardiopulmonary exercise was a stronger predictor of mortality at six months than VO2 or six-minute walk distance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/41\">",
"     41",
"    </a>",
"    ]. However, further validation of this finding is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32497735\">",
"    <span class=\"h2\">",
"     Ventricular ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe ventricular ectopy after exercise may also be predictive of increased mortality. This was suggested in an analysis of 2123 patients with an LVEF &le;35 percent who underwent symptom-limited exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/42\">",
"     42",
"    </a>",
"    ]. Severe ventricular ectopy (defined as ventricular triplets, sustained or nonsustained ventricular tachycardia (VT), ventricular flutter, polymorphic VT, or ventricular fibrillation) was present in 140 patients (7 percent) during recovery. At three years, patients with severe ventricular ectopy after exercise had a significantly greater mortality rate than those without this arrhythmia (37 versus 22 percent). The increase in risk was seen both in patients with an implantable defibrillator (ICD) and in those without an ICD, suggesting that ventricular ectopy is an indicator of the risk of disease progression rather than just the risk of future arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of ICD shocks in patients with HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H21#H21\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Prognostic significance of ICD shocks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2002 task force of the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    has given a class I recommendation to the use of exercise testing with ventilatory gas analysis for the purpose of evaluating exercise capacity in patients with heart failure who are being considered for cardiac transplantation (",
"    <a class=\"graphic graphic_table graphicRef65640 \" href=\"UTD.htm?2/53/2908\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/44\">",
"     44",
"    </a>",
"    ]. It must be emphasized that the value for peak VO2 should be interpreted in the context of the patient's age, lifestyle, goals, and current therapies, such as beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     USE OF EXERCISE HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although peak VO2 is one of the most important prognostic variables, direct assessment of exercise hemodynamics may improve the prognostic evaluation of patients with HF. One study of 219 patients who underwent exercise testing while being monitored with a Swan-Ganz catheter found that peak exercise stroke work index was the most powerful prognostic variable; the two year survival for those with a stroke work index &le;30",
"    <span class=\"nowrap\">",
"     gm/m2",
"    </span>",
"    was 54 percent compared with 91 percent for those with an index &gt;30",
"    <span class=\"nowrap\">",
"     gm/m2",
"    </span>",
"    (p&lt;0.0001) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/26\">",
"     26",
"    </a>",
"    ]. Among patients with a relatively low peak VO2, those who had a normal cardiac output response to exercise had an excellent two year survival (87 versus 58 percent in the others) (",
"    <a class=\"graphic graphic_figure graphicRef56121 \" href=\"UTD.htm?13/14/13550\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXERCISE TRAINING IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the use of exercise training to improve symptoms in selected patients with CHF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .) Training does not improve cardiac function at rest, as estimated from left ventricular ejection fraction, baseline cardiac output, or wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/48\">",
"     48",
"    </a>",
"    ]. It can, however, have the following benefits in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased peak VO2, peak cardiac output, and leg blood flow during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/48,50\">",
"       48,50",
"      </a>",
"      ]. These improvements may be related to an increase in peak early diastolic filling rate of the left ventricle at rest and during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved muscle energetics so that oxygen utilization becomes more efficient, allowing a similar amount of work to be performed at a lower heart rate, rate-pressure product, and minute ventilation (indicating improved gas exchange) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reversal of the abnormalities in mitochondrial density and ultrastructure and on fiber type distribution in skeletal muscle seen with HF. For example, one study prospectively randomized 18 patients with HF to an ambulatory training or to a control group that was physically inactive [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/54\">",
"       54",
"      </a>",
"      ]. After six months, the patients who exercised had a significant increase in mitochondrial density and enhanced oxidative enzyme activity and a concomitant reshift to type I slow-twitch fibers. These changes appear to be unrelated to changes in peripheral perfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"       \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial reversal of endothelial dysfunction with restoration of endothelium-mediated flow-dependent dilation, possibly due to enhanced endothelial release of nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with an ischemic cardiomyopathy, there is an improvement in both thallium activity within the myocardium and the contractile response of dysfunctional myocardium to low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ; this correlates with an increase in collaterals [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction in plasma brain natriuretic peptide values. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, more exercise can be performed before reaching the anaerobic threshold (",
"    <a class=\"graphic graphic_figure graphicRef82041 \" href=\"UTD.htm?41/55/42877\">",
"     figure 10",
"    </a>",
"    ). In one study, for example, exercise training in stable patients with a mean left ventricular ejection fraction of 20 percent led to an increase in peak VO2 from 13.2 to 15.6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/48\">",
"     48",
"    </a>",
"    ]. Another study reported that the improvement in VO2 was not related to baseline central hemodynamics, but was greater in patients with a lower baseline VO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, all three determinants of peak exercise - cardiac efficiency, pulmonary gas exchange, and skeletal muscle metabolism - may be improved by exercise training. The ability to perform more work with less energy expenditure may have the following benefits for the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There may be an improvement in symptoms such as dyspnea and fatigue.",
"     </li>",
"     <li>",
"      The lower rate-pressure product may allow patients with coronary disease to perform their daily tasks with fewer symptoms and less disability.",
"     </li>",
"     <li>",
"      There may be a reduction in sympathetic tone and an increase in vagal tone at rest, thereby restoring autonomic cardiovascular control towards normal [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/58\">",
"       58",
"      </a>",
"      ]. To the degree that these changes reduce systemic vascular resistance and cardiac afterload, they may lead to an improvement in cardiac performance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was previously no proof that improvement in peak VO2, as can be induced by exercise training, is associated with improvements in outcomes. In HF-ACTION, every 6 percent increase in peak VO2, adjusted for other significant predictors, was associated with a 5 percent lower risk of the primary end point, a 4 percent lower risk of the secondary end point of time to cardiovascular mortality or cardiovascular hospitalization, an 8 percent lower risk of cardiovascular mortality or heart failure hospitalization, and a 7 percent lower all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, there is sufficient evidence of an improvement in symptoms and exercise capacity that we recommend that all stable patients with symptomatic heart failure participate in an exercise training program [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of exercise programs on outcomes was studied in the HF ACTION trial, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled nitric oxide, a selective pulmonary vasodilator, reduces pulmonary vascular resistance in patients with secondary pulmonary hypertension, including those with congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/60\">",
"     60",
"    </a>",
"    ]. One study of 14 patients undergoing transplantation evaluation found that inhaled nitric oxide (40 ppm) increased exercise capacity, particularly in those with more severe HF who had a high pulmonary artery pressure, large left ventricular volume, and lower right ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/61\">",
"     61",
"    </a>",
"    ]. Inhaled nitric oxide also improves ventilation-perfusion mismatch and gas exchange, resulting in an increase in atrial O2 and reductions in the alveolar-arterial difference in partial pressure of O2 and the ratio of physiologic dead space to tidal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=see_link\">",
"     \"Inhaled nitric oxide in adults with pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical practice, many physicians follow the symptoms and signs of patients with heart failure as a guide to their course and prognosis. Nevertheless, serial assessment of maximal exercise capacity in patients with HF every three to six months is an important method to evaluate both the therapeutic response to pharmacologic intervention as well as prognosis. Determination of functional capacity is now an outpatient performance measure as published by the",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    Performance Measures for Chronic Heart Failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mild heart failure (NYHA class I or II) can be evaluated by repetitive treadmill exercise testing without a metabolic cart assessment for maximal oxygen consumption (ie, peak VO2) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ); in this setting, total exercise duration can be used as an objective measure of functional capacity.",
"   </p>",
"   <p>",
"    In comparison, patients who present with or progress to moderate-to-severe heart failure (NYHA class III or IV) should be referred to a center with the capability to perform VO2 determinations. The specific method used to measure VO2 is less important as long as the test is performed and interpreted in a consistent manner. Improved exercise capacity is often associated with an increase in peak VO2 in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7241/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/1\">",
"      Working Group on Cardiac Rehabilitation &amp; Excercise Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise testing in chronic heart failure patients. Eur Heart J 2001; 22:37.",
"     </a>",
"    </li>",
"    <li>",
"     Dennis C. Rehabilitation of patients with coronary artery disease. In: Heart Disease, A Textbook of Cardiovascular Medicine, 4th ed, Braunwald E (Ed), Saunders, Philadelphia 1992. p.1382.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/3\">",
"      McElroy PA, Janicki JS, Weber KT. Cardiopulmonary exercise testing in congestive heart failure. Am J Cardiol 1988; 62:35A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/4\">",
"      Reddy HK, Weber KT, Janicki JS, McElroy PA. Hemodynamic, ventilatory and metabolic effects of light isometric exercise in patients with chronic heart failure. J Am Coll Cardiol 1988; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/5\">",
"      Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 1998; 136:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/6\">",
"      Zugck C, Kr&uuml;ger C, D&uuml;rr S, et al. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J 2000; 21:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/7\">",
"      Shah MR, Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2001; 88:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/8\">",
"      Passantino A, Lagioia R, Mastropasqua F, Scrutinio D. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice. J Am Coll Cardiol 2006; 48:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/9\">",
"      Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997; 30:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/10\">",
"      Sullivan MJ, Cobb FR. Central hemodynamic response to exercise in patients with chronic heart failure. Chest 1992; 101:340S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/11\">",
"      Colucci WS. In vivo studies of myocardial beta-adrenergic receptor pharmacology in patients with congestive heart failure. Circulation 1990; 82:I44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/12\">",
"      Bristow MR, Minobe WA, Raynolds MV, et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993; 92:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/13\">",
"      Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999; 34:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/14\">",
"      Walsh JT, Andrews R, Johnson P, et al. Inspiratory muscle endurance in patients with chronic heart failure. Heart 1996; 76:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/15\">",
"      Tikunov B, Levine S, Mancini D. Chronic congestive heart failure elicits adaptations of endurance exercise in diaphragmatic muscle. Circulation 1997; 95:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/16\">",
"      Smith AA, Cowburn PJ, Parker ME, et al. Impaired pulmonary diffusion during exercise in patients with chronic heart failure. Circulation 1999; 100:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/17\">",
"      Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. Circulation 1988; 77:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/18\">",
"      Buller NP, Poole-Wilson PA. Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. Br Heart J 1990; 63:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/19\">",
"      de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/20\">",
"      Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/21\">",
"      Forman DE, Clare R, Kitzman DW, et al. Relationship of age and exercise performance in patients with heart failure: the HF-ACTION study. Am Heart J 2009; 158:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/22\">",
"      Elmariah S, Goldberg LR, Allen MT, Kao A. Effects of gender on peak oxygen consumption and the timing of cardiac transplantation. J Am Coll Cardiol 2006; 47:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/23\">",
"      O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/24\">",
"      Osada N, Chaitman BR, Miller LW, et al. Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation. J Am Coll Cardiol 1998; 31:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/25\">",
"      Chomsky DB, Lang CC, Rayos GH, et al. Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates. Circulation 1996; 94:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/26\">",
"      Metra M, Faggiano P, D'Aloia A, et al. Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. J Am Coll Cardiol 1999; 33:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/27\">",
"      Mancini D, Katz S, Donchez L, Aaronson K. Coupling of hemodynamic measurements with oxygen consumption during exercise does not improve risk stratification in patients with heart failure. Circulation 1996; 94:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/28\">",
"      Gitt AK, Wasserman K, Kilkowski C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation 2002; 106:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/29\">",
"      Paraskevaidis IA, Adamopoulos S, Kremastinos DT. Dobutamine echocardiographic study in patients with nonischemic dilated cardiomyopathy and prognostically borderline values of peak exercise oxygen consumption: 18-month follow-up study. J Am Coll Cardiol 2001; 37:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/30\">",
"      Flynn KE, Lin L, Moe GW, et al. Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. Am Heart J 2012; 163:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/31\">",
"      O'Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. Circ Heart Fail 2012; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/32\">",
"      Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1997; 29:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/33\">",
"      Milani RV, Mehra MR, Reddy TK, et al. Ventilation/carbon dioxide production ratio in early exercise predicts poor functional capacity in congestive heart failure. Heart 1996; 76:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/34\">",
"      Arena R, Myers J, Abella J, et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007; 115:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/35\">",
"      Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 2000; 101:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/36\">",
"      Wasserman K, Zhang YY, Gitt A, et al. Lung function and exercise gas exchange in chronic heart failure. Circulation 1997; 96:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/37\">",
"      Robbins M, Francis G, Pashkow FJ, et al. Ventilatory and heart rate responses to exercise : better predictors of heart failure mortality than peak oxygen consumption. Circulation 1999; 100:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/38\">",
"      Ponikowski P, Francis DP, Piepoli MF, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001; 103:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/39\">",
"      Baba R, Nagashima M, Goto M, et al. Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol 1996; 28:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/40\">",
"      Davies LC, Wensel R, Georgiadou P, et al. Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. Eur Heart J 2006; 27:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/41\">",
"      Sun XG, Hansen JE, Stringer WW. Oxygen uptake efficiency plateau best predicts early death in heart failure. Chest 2012; 141:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/42\">",
"      O'Neill JO, Young JB, Pothier CE, Lauer MS. Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure. J Am Coll Cardiol 2004; 44:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/43\">",
"      Dries DL, Verdino RJ, Kowal RC. Postexercise severe ventricular ectopy in heart failure patients: new marker for aggregate risk. J Am Coll Cardiol 2004; 44:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/44\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/45\">",
"      Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004; 43:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/46\">",
"      O'Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005; 111:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/47\">",
"      Gardner RS, McDonagh TA, MacDonald M, et al. Who needs a heart transplant? Eur Heart J 2006; 27:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/48\">",
"      Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail 2012; 5:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/49\">",
"      Tyni-Lenn&eacute; R, Gordon A, Jansson E, et al. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/50\">",
"      Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992; 85:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/51\">",
"      Belardinelli R, Georgiou D, Cianci G, Purcaro A. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 1996; 132:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/52\">",
"      Minotti JR, Johnson EC, Hudson TL, et al. Skeletal muscle response to exercise training in congestive heart failure. J Clin Invest 1990; 86:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/53\">",
"      Adamopoulos S, Coats AJ, Brunotte F, et al. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 1993; 21:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/54\">",
"      Hambrecht R, Fiehn E, Yu J, et al. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 1997; 29:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/55\">",
"      Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/56\">",
"      Belardinelli R, Georgiou D, Ginzton L, et al. Effects of moderate exercise training on thallium uptake and contractile response to low-dose dobutamine of dysfunctional myocardium in patients with ischemic cardiomyopathy. Circulation 1998; 97:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/57\">",
"      Meyer K, G&ouml;rnandt L, Schwaibold M, et al. Predictors of response to exercise training in severe chronic congestive heart failure. Am J Cardiol 1997; 80:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/58\">",
"      Coats AJ. Exercise rehabilitation in chronic heart failure. J Am Coll Cardiol 1993; 22:172A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/59\">",
"      McKelvie RS, Teo KK, McCartney N, et al. Effects of exercise training in patients with congestive heart failure: a critical review. J Am Coll Cardiol 1995; 25:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/60\">",
"      Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/61\">",
"      Koelling TM, Kirmse M, Di Salvo TG, et al. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998; 81:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/62\">",
"      Matsumoto A, Momomura S, Sugiura S, et al. Effect of inhaled nitric oxide on gas exchange in patients with congestive heart failure. A randomized, controlled trial. Ann Intern Med 1999; 130:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7241/abstract/63\">",
"      Bonow RO, Bennett S, Casey DE Jr, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2005; 46:1144.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3503 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7241=[""].join("\n");
var outline_f7_4_7241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASUREMENT OF EXERCISE CAPACITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Peak VO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ventilatory threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Six-minute walk test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXERCISE CAPACITY IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PEAK VO2 AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32497339\">",
"      Predictive value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Additional predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32496427\">",
"      OTHER PREDICTIVE EXERCISE PARAMETERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32497388\">",
"      Six-minute walk test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32496488\">",
"      Exercise duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32496435\">",
"      Ventilatory efficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32496471\">",
"      Oxygen uptake efficiency parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32497735\">",
"      Ventricular ectopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      USE OF EXERCISE HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXERCISE TRAINING IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3503|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/41/30366\" title=\"figure 1\">",
"      Response to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/45/7902\" title=\"figure 2\">",
"      Exercise in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/58/30638\" title=\"figure 3\">",
"      Muscle abnormalities in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/38/21101\" title=\"figure 4\">",
"      VO2 and survival in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/10/42157\" title=\"figure 5\">",
"      Cardiopul exercise outc HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/12/27853\" title=\"figure 6\">",
"      Stroke work index surv HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/18/38189\" title=\"figure 7\">",
"      VE VCO2 and survival in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3342\" title=\"figure 8\">",
"      Outcome CRI VE VCO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/14/13550\" title=\"figure 9\">",
"      Outcome SWI VO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/55/42877\" title=\"figure 10\">",
"      Exercise training in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/53/2908\" title=\"table 1\">",
"      ACC AHA gas exchange exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=related_link\">",
"      Skeletal muscle dysfunction and exercise intolerance in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_4_7242="AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma";
var content_f7_4_7242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Lawrence D Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Wei Ai, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/4/7242/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/4/7242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1531008\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection results in impaired cellular immunity, a condition known to predispose persons to develop neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As the lifespan of HIV-infected patients has increased, malignancies have become a known cause of morbidity and mortality in this population. Before the advent of highly active antiretroviral therapy (HAART), malignancies accounted for approximately 10 percent of HIV-related deaths. Since the routine implementation of HAART therapy, a cancer diagnosis is made in over 40 percent of HIV-infected patients during the course of the HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/5\">",
"     5",
"    </a>",
"    ], and over 28 percent of HIV-related deaths are attributable to malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three AIDS-defining malignancies: Kaposi's sarcoma, non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype, and invasive cervical carcinoma. In addition, non-AIDS-defining malignancies contribute to mortality in HIV-infected persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnostic approach to AIDS-related systemic NHL will be reviewed here. The epidemiology, risk factors, pathobiology, and treatment of AIDS-related systemic NHL are discussed separately, as are the diagnosis of AIDS-related primary central nervous system lymphoma and primary effusion lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201064119\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of non-Hodgkin lymphoma (NHL) varies tremendously depending upon the type of lymphoma and the areas of involvement. Some NHLs behave indolently with lymphadenopathy waxing and waning over years. Others are highly aggressive, resulting in death within weeks if left untreated. Although indolent lymphoma may occur, most NHL in the HIV-seropositive population is clinically aggressive. Less common presentations of systemic NHL include abnormal laboratory results, such as unexplained cytopenias, hypercalcemia, elevated lactate dehydrogenase, or tumor lysis syndrome (ie, lactic acidosis, hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Abnormal laboratory results'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-associated lymphoma is most commonly diagnosed in patients with advanced HIV, a low CD4 count (often",
"    <span class=\"nowrap\">",
"     &lt;100/microL),",
"    </span>",
"    high HIV viral load, and a prior diagnosis of AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Since the introduction of highly antiretroviral therapy, the incidence of HIV-associated lymphoma has declined and the median CD4 count at diagnosis has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. The proportion of patients with stage IV disease (56 to 84 percent), bone marrow (13 to 22 percent) or leptomeningeal (6 to 16 percent) involvement has not changed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/14-16,19-21\">",
"     14-16,19-21",
"    </a>",
"    ]. Although the risk of NHL continues to be directly related to CD4 count, data from the UK Collaborative HIV Cohort demonstrate a median CD4 count",
"    <span class=\"nowrap\">",
"     &gt;200/mm3",
"    </span>",
"    in those presenting with systemic NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/22\">",
"     22",
"    </a>",
"    ]. While the incidence of AIDS-defining illnesses (ADI) has decreased overall since the introduction of highly active antiretroviral therapy, the proportion of ADIs attributable to NHL has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. NHL is one of the most common and most frequently fatal of the AIDS-defining illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/24\">",
"     24",
"    </a>",
"    ], though survival has improved significantly since the introduction of highly active antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/25\">",
"     25",
"    </a>",
"    ]. HIV-associated lymphoma typically presents in an aggressive fashion, with diffuse large B-cell lymphoma and Burkitt lymphoma comprising the majority of cases; low-grade (indolent) lymphomas are less common and typically occur in patients with relatively high CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with lymphoma in the HIV-negative population, systemic lymphoma in the HIV-positive population is characterized by frequent B symptoms (ie, fever, weight loss, night sweats), extranodal disease, involvement of unusual locations (eg, body cavity, rectum, soft tissue), and advanced stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. Often, the clinical manifestations of systemic NHL in HIV-infected patients are protean, with no pathognomonic features. Initial symptoms include diffuse adenopathy, low-grade fevers, and minor hematologic or biochemical abnormalities that may be more suggestive of a viral or bacterial infection. A subset of HIV-positive patients with NHL will present with fever of unknown (FUO) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In two case series, lymphoma was the underlying etiology in approximately 6 percent of HIV-infected patients with FUO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A subsequent case-control study found that of patients with FUO, lymphoma was the etiology in 14 percent of patients on antiretroviral therapy and 8 percent of those who were not (a difference that was not statistically significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H5#H5\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of more advanced lymphoma include bulky adenopathy of virtually any anatomic location, and symptoms related to the mass effect of these tumors. Mass lesions can cause obstruction of, or bleeding within, the hollow viscera. Tumor infiltration can also interfere with normal organ function. The most common sites of extranodal involvement are the gastrointestinal tract, bone marrow, liver, lung, and central nervous system. These extranodal sites are commonly involved in aggressive NHL, regardless of HIV status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most information regarding gastrointestinal lymphoma in the HIV-positive population comes from the era before the routine implementation of highly active antiretroviral therapy (HAART), since this condition is most commonly associated with advanced HIV and low CD4 counts. Based on older series, the gastrointestinal tract is the presenting site of AIDS-related systemic lymphoma in 30 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/16,33-35\">",
"     16,33-35",
"    </a>",
"    ], and is the most frequent site of extranodal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. A more recent series indicates the rate of GI involvement to be 14 percent of AIDS-related lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/15\">",
"     15",
"    </a>",
"    ]. The area of gastrointestinal tract involvement is different from that in the non-HIV setting. Virtually any area of the gastrointestinal tract may be involved, including the oral cavity, esophagus, bile duct, pancreas, mesentery, small bowel, perianal area, and anal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/28,33,34,36,38\">",
"     28,33,34,36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 48 patients with HIV-associated gastrointestinal lymphoma, involvement was multifocal in 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/33\">",
"     33",
"    </a>",
"    ]. Areas of involvement included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stomach &mdash; 50 percent",
"     </li>",
"     <li>",
"      Duodenum &mdash; 25 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Perianal/anal",
"      </span>",
"      &mdash; 15 percent",
"     </li>",
"     <li>",
"      Oropharynx &mdash; 10 percent",
"     </li>",
"     <li>",
"      Small bowel &mdash; 8 percent",
"     </li>",
"     <li>",
"      Esophagus &mdash; 6 percent",
"     </li>",
"     <li>",
"      Liver, cecum, and rectum &mdash; each &lt;5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major presenting features of these tumors are abdominal or perianal pain, fever, diarrhea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss; life-threatening complications such as bleeding, perforation, and obstruction have been reported in 16 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/33-36,39,40\">",
"     33-36,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Liver, lung, and bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver, lung, and bone marrow are involved in about one-third of patients with AIDS-related systemic lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic involvement may be clinically silent or associated with pain, elevated serum liver enzymes, or signs and symptoms of biliary obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary disease may present as a mass lesion or a parenchymal pattern of involvement with multinodular densities and diffuse interstitial infiltrates [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/42\">",
"       42",
"      </a>",
"      ]. Pleural effusions eventually develop in almost 70 percent of those with pulmonary involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9750?source=see_link\">",
"       \"Pulmonary manifestations of HIV-associated lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The bone marrow is affected in approximately 25 to 35 percent of patients at the time of presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/41,43\">",
"       41,43",
"      </a>",
"      ]. Bone marrow involvement may manifest as peripheral cytopenias (ie, anemia, neutropenia, and thrombocytopenia) or related symptoms such as weakness and easy fatigability, infections of variable severity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Meninges and central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 20 percent of patients with HIV-associated systemic lymphoma have spread to the central nervous system (CNS) at the time of presentation, typically in the form of lymphomatous meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. It is not clear that patients with HIV infection are inherently at higher risk for leptomeningeal involvement. It is more likely that the high incidence of CNS disease is related to the greater frequency of extranodal disease and Burkitt histology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. Lymphomatous meningitis may also present at the time of disease recurrence, particularly in patients at high risk for occult leptomeningeal involvement not treated with intrathecal prophylactic therapy during initial treatment of the lymphoma. Primary CNS lymphoma (ie, NHL of the CNS without systemic disease) accounts for up to 15 percent of NHLs in HIV-infected patients, although its incidence has decreased since the advent of highly active antiretroviral therapy (HAART). Primary CNS lymphoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of leptomeningeal disease may not be apparent from the history and physical examination. Almost one-quarter of patients with leptomeningeal involvement are asymptomatic and, even when symptoms occur, only a minority have meningeal signs (ie, nuchal rigidity, Kernig sign, Brudzinski sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/44\">",
"     44",
"    </a>",
"    ]. Other symptoms of leptomeningeal involvement include headache, radicular pain, vague back or neck pain, mental status changes, focal weakness or sensory loss, and cranial nerve palsies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link&amp;anchor=H7302347#H7302347\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8194370\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201065365\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient with suspected AIDS-related NHL starts with a complete history and physical examination. Specific historical features and physical findings that are important to the diagnosis of NHL in both the HIV seropositive and HIV seronegative populations are presented in detail separately. The following sections review aspects of the evaluation that are specific for patients with HIV. The evaluation choice of specific diagnostic tests varies with the organ site of suspected lymphoma involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although few patients diagnosed early in the HIV epidemic were cured of their lymphoma, the introduction of highly active antiretroviral therapy (HAART) in the late 1990s resulted in a marked improvement in the ability of these patients to tolerate standard chemotherapy regimens and in clinical outcomes that now approach those in the general population. Thus, a diagnosis of AIDS-related NHL should not discourage appropriate surgical procedures for diagnosis and therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201065586\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the diagnosis may be suggested by findings on imaging studies, a definitive diagnosis of NHL requires a biopsy. A biopsy should be obtained urgently if an aggressive NHL is suspected. Approximately 25 to 35 percent of AIDS-related lymphomas can be found in the bone marrow at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]; thus, bone marrow biopsy is part of the standard staging evaluation and may be a useful diagnostic procedure when obtaining tissue at other sites would result in greater morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link&amp;anchor=H6237308#H6237308\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Lymph node and tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy has a diagnostic yield that ranges from 75 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The ideal biopsy site is not always clear upon presentation. Initial lymph node biopsies may reveal HIV-related hyperplasia. As such, multiple biopsies may be required to ascertain the diagnosis. 18F-2-deoxyglucose positron-emission tomography (FDG-PET) may be helpful in identifying the most metabolically avid and potentially highest yield site for biopsy. Only excisional biopsy of an intact node consistently allows sufficient tissue for histologic, immunologic, molecular biologic assessment, and classification by experienced hematopathologists. While fine needle aspiration (FNA) of enlarged lymph nodes may demonstrate lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], a negative result on FNA does not exclude the presence of lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/52\">",
"     52",
"    </a>",
"    ], and FNA is generally not recommended for diagnosis in patients with suspected lymphoma, as it does not always provide the diagnosis of the specific subtype of lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Type of biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When evaluating the tissue that has been obtained, it is important to appreciate that AIDS-related lymphomas have a different pathogenesis and behavior than lymphomas of similar histology that occur in the HIV-seronegative population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Overall, 5 to 20 percent of these tumors have polyclonal populations of cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/53,57,58\">",
"     53,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GI tract evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When gastrointestinal involvement is suspected, the evaluation typically includes a physical examination, imaging studies, upper and lower endoscopy, and biopsy. Laparotomy and laparoscopy are typically reserved for patients with complications such as perforation or obstruction. The physical examination is often normal, but may reveal a mass at the involved site.",
"   </p>",
"   <p>",
"    Computed tomography (CT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contrast radiography are usually the initial diagnostic modalities performed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/37,38,59\">",
"     37,38,59",
"    </a>",
"    ]. Plain films of the abdomen are often unrevealing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/37\">",
"     37",
"    </a>",
"    ]. Hepatic or splenic involvement manifests as low-attenuation mass lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/37\">",
"     37",
"    </a>",
"    ]. Although CT findings of lymphomas of the small intestine tend to be nonspecific, several appearances are highly suggestive of this diagnosis. One or more of the following is encountered in at least 80 percent of small intestinal lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Solitary lesions that cause annular infiltration",
"     </li>",
"     <li>",
"      Wall thickening",
"     </li>",
"     <li>",
"      Focal cavitary lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endoscopy allows for detection and biopsy of abnormalities located in the esophagus, stomach, or colon. Although technically difficult, endoscopic evaluation of the small bowel with biopsy of lesions can also be diagnostic. Proximal small bowel lesions may be detected by \"push\" enteroscopy, while lesions in the distal small bowel may be assessed with intubation of the terminal ileum during colonoscopy. Endoscopic findings are similar to those of gastrointestinal lymphoma in the non-HIV positive population and include polypoid, bulky lesions or well-defined ulcers presenting as single or multiple lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of gastrointestinal lymphoma may be suggested by endoscopic or imaging findings, but must be confirmed by biopsy. Suspicious appearing lesions and normal appearing mucosa should both be biopsied since multifocal disease with involvement of tissue that appears to be unaffected on initial visualization is not uncommon. (See",
"    <a class=\"local\" href=\"#H1201065586\">",
"     'Biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of clinical pulmonary involvement with NHL ranges from 6 to 31 percent, while autopsy studies show a higher percentage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. The lung is occasionally the initial site of disease, but more often, it is involved in association with other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/64\">",
"     64",
"    </a>",
"    ]. In the setting of solitary pulmonary lymphoma, lung biopsy is required for the diagnosis of parenchymal disease. Transbronchial and open lung biopsy have reported yields of up to 58 and 75 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50\">",
"     50",
"    </a>",
"    ], and transthoracic needle biopsy was diagnostic in 5 of 10 patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/65\">",
"     65",
"    </a>",
"    ]. Bronchoalveolar lavage or bronchial brushings are very low yield procedures for the diagnosis of pulmonary lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50\">",
"     50",
"    </a>",
"    ]. However, they may exclude opportunistic infections in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9750?source=see_link\">",
"     \"Pulmonary manifestations of HIV-associated lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical radiographic findings and approximate frequencies include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hilar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mediastinal lymphadenopathy &mdash; 50 percent",
"     </li>",
"     <li>",
"      Pleural effusions &mdash; 44 percent",
"     </li>",
"     <li>",
"      Lobar consolidation &mdash; 40 percent",
"     </li>",
"     <li>",
"      Reticular infiltrates &mdash; 24 percent",
"     </li>",
"     <li>",
"      Mass lesions &mdash; 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography (CT) scans of the chest in these patients modestly improve the diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50,66\">",
"     50,66",
"    </a>",
"    ]. In one series, pulmonary nodules were detected in 50 percent and pleural effusions in 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50\">",
"     50",
"    </a>",
"    ]. In comparison, CT scanning did not seem to increase the detection rate of hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal lymphadenopathy.",
"   </p>",
"   <p>",
"    Pleural effusions associated with pulmonary lymphomatous involvement are exudative, often containing very high concentrations of lactate dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50\">",
"     50",
"    </a>",
"    ]. The yield of pleural fluid cytology and pleural biopsy is about 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/50,67\">",
"     50,67",
"    </a>",
"    ]. This type of pleural effusion is different from that seen in primary effusion lymphomas, in which there is no mass effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201066293\">",
"    <span class=\"h2\">",
"     CNS evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, 5 to 20 percent of patients with HIV-associated systemic lymphoma have spread to the central nervous system (CNS) at the time of presentation, typically in the form of lymphomatous meningitis. An evaluation of the CNS is incorporated into the staging evaluation of select patients with AIDS-related NHL. Risk factors for CNS involvement include Burkitt histology, bone marrow involvement, involvement of more than one extranodal site with increased serum LDH, paranasal sinus or paraspinal involvement, CD4 count",
"    <span class=\"nowrap\">",
"     &lt;100/microL",
"    </span>",
"    and Epstein-Barr virus (EBV) infection of the primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/45,68-70\">",
"     45,68-70",
"    </a>",
"    ]. The risk of CNS involvement at diagnosis and of CNS relapse appears to have decreased in the HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/69\">",
"     69",
"    </a>",
"    ]. The diagnosis of primary CNS lymphoma (ie, NHL of the CNS without systemic disease) is discussed separately. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Staging'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with symptoms suggesting involvement of the CNS should be evaluated for leptomeningeal metastases (LM). The diagnosis of LM is made based upon the pathologic evaluation of a sample of cerebrospinal fluid (CSF) interpreted within the clinical context. A careful history and physical examination should evaluate for multifocal involvement. Patients suspected of having LM should be evaluated promptly with neuroimaging and CSF analysis. Radiographic evaluation with MRI of the brain and spine should be performed prior to lumbar puncture (LP) or ventricular tap, because the latter procedures can cause iatrogenic meningeal irritation and enhancement on imaging. Patients with an Ommaya reservoir in place should have CSF samples collected from both the Ommaya reservoir (ie, ventricular tap) and lumbar space (ie, LP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H6052480#H6052480\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Neuroimaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CSF analysis should include cell counts, protein and glucose measurements, cytology, and flow cytometry. Immunoglobulin heavy-chain gene (IgH) rearrangement studies by polymerase chain reaction (PCR) may be helpful in the evaluation of pauci-cellular samples, and may be considered if the former tests do not yield a diagnosis yet clinical suspicion remains high. One study of CSF analysis in 50 patients with systemic AIDS-related NHL reported that the sensitivity and specificity of EBV-DNA detection in CSF for CNS involvement by lymphoma were 90 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CSF often reveals an elevated protein concentration and a lymphocytic predominant pleocytosis. Glucose concentration is usually normal, but may be lowered in the presence of leptomeningeal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. There may be difficulty distinguishing between reactive and malignant cells or distinguishing reactive cells in the CSF from small cells of medulloblastoma as distinct from malignant B-cells. In such cases, immunophenotypic analysis using antibodies against lymphocytic antigens is particularly helpful in establishing the lymphoid origin and clonality of the malignant cells, when present, and to differentiate between B- and T-cell subtypes.",
"   </p>",
"   <p>",
"    The diagnosis of leptomeningeal involvement can be made by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of lymphoma nodules on lumbar nerve roots via scanning procedures such as CT or MRI in patients with pathologically diagnosed NHL",
"     </li>",
"     <li>",
"      Identification of malignant cells in the CSF cytospin",
"     </li>",
"     <li>",
"      Immunocytologic identification of clonal B-cells in the CSF",
"     </li>",
"     <li>",
"      Demonstration of immunoglobulin gene rearrangement of B cells in the cerebrospinal fluid (CSF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AIDS-related systemic lymphoma is generally suspected in a patient with advanced HIV presenting with adenopathy, prolonged B symptoms (fever, weight loss, night sweats), unexplained hematologic or biochemical abnormalities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs or symptoms attributable to the infiltration of extralymphatic tissues. Non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype is an AIDS-defining malignancy and is confirmed by the identification of both:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection &mdash; HIV-associated lymphoma is most commonly diagnosed in patients with advanced HIV, a CD4 count",
"      <span class=\"nowrap\">",
"       &lt;100/microL,",
"      </span>",
"      high HIV viral load, and a prior diagnosis of AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. NHL is currently one of the most common and most frequently fatal of the AIDS-defining illnesses [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/24\">",
"       24",
"      </a>",
"      ], though survival has improved significantly since the introduction of highly active antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma &mdash; A biopsy is required for the diagnosis and classification of NHL. This should be obtained urgently if an aggressive NHL is suspected. The diagnosis of lymphoma is based upon the evaluation of histologic, immunophenotypic, and genetic studies interpreted in the context of the clinical scenario. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Studies on excised tissue'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a diagnosis of AIDS-related lymphoma is made, the specific subtype of NHL must be determined in order to guide therapy. The World Health Organization has classified HIV-related lymphomas into three categories: lymphomas also occurring in immunocompetent patients, those specifically occurring in HIV-positive patients, and those occurring in other immunodeficiency states (",
"    <a class=\"graphic graphic_table graphicRef79517 \" href=\"UTD.htm?24/49/25371\">",
"     table 1",
"    </a>",
"    ). The most common NHL subtypes seen in this population are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B-cell lymphomas (DLBCL) &mdash; DLBCL is a heterogeneous group of tumors consisting of large, atypical lymphoid cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern, and a high proliferation fraction. These tumor cells typically express pan-B cell antigens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Burkitt lymphoma &mdash; Burkitt lymphoma cells are monomorphic, medium-sized cells with round nuclei, multiple nucleoli, and basophilic cytoplasm. Prominent cytoplasmic lipid vacuoles are usually evident and there is an extremely high rate of proliferation as well as a high rate of apoptotic cell death and a &ldquo;starry-sky&rdquo; pattern. There is a strong, but not uniform, association between the site of the c-MYC oncogene and one of three locations on immunoglobulin genes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasmablastic lymphoma &mdash; Plasmablastic lymphoma is a rare neoplastic disorder encountered in the HIV seropositive population, usually in those with relatively low CD4 counts. Typical presentation is in the oral cavity, however extraoral involvement has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. These neoplasms, like primary effusion lymphoma (PEL), are driven by HHV8 (human herpesvirus 8) and are thought to be the solid tissue correlate of PEL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/76\">",
"       76",
"      </a>",
"      ]. They are associated with an aggressive course and poor survival [",
"      <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"       \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While DLBCL and plasmablastic lymphoma usually arise in those with more advanced HIV infection, with a CD4 count typically &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/8,77\">",
"     8,77",
"    </a>",
"    ], Burkitt lymphoma may occur in the setting of a wide range of CD4 counts. As such, the frequency of NHL subtypes is changing as more patients are being diagnosed and treated aggressively for HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H4#H4\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'Specific NHL subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This morphologic classification of AIDS-related lymphomas is somewhat artificial. The morphologic features of Burkitt lymphoma and DLBCL may overlap and morphologic examination does not always predict response to therapy. In addition, DLBCL that arises within the environment of HIV-related multicentric Castleman's disease appears to be a separate clinicopathologic entity containing",
"    <span class=\"nowrap\">",
"     KSHV/HHV8",
"    </span>",
"    (human herpesvirus 8) virus and demonstrating a pre-plasma cell phenotype with",
"    <span class=\"nowrap\">",
"     plasmacytic/plasmablastic",
"    </span>",
"    morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Burkitt lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8194421\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of AIDS-related lymphoma includes other disorders with a similar presentation. As described above, most patients with AIDS-related NHL present with unexplained fever, drenching night sweats, or weight loss (systemic B symptoms). These symptoms can also be seen in various opportunistic infections, such as disseminated mycobacterial or fungal infections, multicentric Castleman&rsquo;s disease, Hodgkin lymphoma, and Kaposi&rsquo;s sarcoma. Patients with systemic symptoms should have blood cultures drawn to rule out disseminated bacterial, mycobacterial, and fungal infections; lumbar puncture as clinically indicated; and those with pulmonary symptoms should have sputum evaluated for acid fast bacilli, Pneumocystis carinii (jirovecii) pneumonia and fungal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24538?source=see_link\">",
"     \"Fever and rash in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link\">",
"     \"Approach to the adult with fever of unknown origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AIDS-related NHL are staged using the Ann Arbor staging system with Cotswold modification (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 2",
"    </a>",
"    ) that is used for staging NHL in the HIV seronegative population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/4/7242/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. This staging system focuses on the number of tumor sites (nodal and extranodal), location, and the presence or absence of systemic (\"B\") symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link&amp;anchor=H6237308#H6237308\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few patients diagnosed early in the HIV epidemic were cured of their lymphoma and the role of staging studies was controversial at that time. However, the introduction of highly active antiretroviral therapy (HAART) in the late 1990s resulted in a marked improvement in the ability of these patients to tolerate standard chemotherapy regimens and clinical outcomes that now approach those in the general population. As such, patients with AIDS-related NHL now undergo a standard staging evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link&amp;anchor=H1225476#H1225476\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with AIDS-related NHL, the stage is determined using information gathered from the history, physical examination, imaging studies, and a unilateral bone marrow biopsy. While the ideal imaging study remains to be defined, we perform a contrast-enhanced computed tomography scan of the chest, abdomen, and pelvis, ideally combined 18F-2-deoxyglucose positron-emission tomography (FDG-PET). This preference is based upon extrapolation of studies in HIV-seronegative patients with NHL. However, as increased FDG uptake can also be seen in reactive lymphadenopathy from active HIV infection, results must be interpreted with caution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'PET scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI of the brain should be performed if there is a high suspicion of CNS involvement based on symptoms or neurologic exam findings. Patients with AIDS-related NHL have an increased risk of central nervous system (CNS) involvement both at the time of diagnosis and during the course of disease. The incidence of CNS involvement varies with NHL subtype. Lumbar puncture should be performed at the time of diagnosis to rule out occult CNS spread for all patients with Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    and for patients with diffuse large B cell lymphoma (DLBCL) who have &gt;2 extranodal sites of disease accompanied by elevated LDH, or specific high-risk sites such as paranasal sinuses, testes, epidural space, and bone marrow. Cerebrospinal fluid should be evaluated with flow cytometric studies in addition to CSF cytology. In patients with a high suspicion of CNS involvement in whom cytology and flow cytometry are not diagnostic, polymerase chain reaction (PCR) for Epstein-Barr virus (EBV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunoglobulin gene rearrangement of B cells may be considered.",
"   </p>",
"   <p>",
"    As described above, it is common for patients with AIDS-related NHL to have involvement of extranodal sites at the time of diagnosis. As such, patients with symptoms or physical findings suggestive of extranodal disease may need additional studies to evaluate for lymphomatous involvement. (See",
"    <a class=\"local\" href=\"#H8194370\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8194304\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentation of non-Hodgkin lymphoma (NHL) varies tremendously depending upon the type of lymphoma and the areas of involvement. When compared with lymphoma in the HIV-negative population, systemic lymphoma in the HIV-positive population is characterized by frequent B symptoms (ie, fever, weight loss, night sweats), extranodal disease, and involvement of unusual locations (eg, body cavity, rectum, soft tissue). The most common sites of extranodal involvement are the gastrointestinal (GI) tract, bone marrow, liver, lung, and central nervous system. (See",
"      <a class=\"local\" href=\"#H1201064119\">",
"       'General'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The GI tract is a frequent presenting site in patients with HIV-associated lymphoma, though the prevalence of GI involvement may have declined in the post-HAART era. Virtually any area of the GI tract may be involved, but the most common sites are the stomach, duodenum,",
"      <span class=\"nowrap\">",
"       perianal/anal",
"      </span>",
"      area, and the oropharynx. The major presenting features are abdominal or perianal pain, fever, diarrhea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight loss; life-threatening complications such as bleeding, perforation and obstruction are not uncommon. When GI involvement is suspected, the evaluation includes imaging studies, upper and lower endoscopy with evaluation of the small bowel, and biopsy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'GI tract evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The liver, lung, and bone marrow are involved in about one-third of patients. Liver involvement may be clinically silent or be associated with pain, elevated serum liver enzymes, or signs and symptoms of biliary obstruction. Lung involvement may present as a mass lesion or as parenchymal disease. Bone marrow involvement may manifest as peripheral cytopenias (ie, anemia, neutropenia, and thrombocytopenia) or related symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Liver, lung, and bone marrow'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 5 to 20 percent of patients with HIV-associated systemic lymphoma have spread to the central nervous system (CNS) at the time of presentation, typically in the form of lymphomatous meningitis (LM). Patients with symptoms suggesting involvement of the CNS (eg, headache, back or neck pain, mental status changes, cranial nerve palsies) should be evaluated for LM. The diagnosis of LM is made based upon the pathologic evaluation of a sample of cerebrospinal fluid (CSF) interpreted within the clinical context. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Meninges and central nervous system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1201066293\">",
"       'CNS evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of AIDS-related systemic lymphoma is usually suspected in a patient with advanced HIV presenting with adenopathy, prolonged B symptoms (fever, weight loss, night sweats), unexplained hematologic or biochemical abnormalities,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs or symptoms attributable to the infiltration of extralymphatic tissues. Non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype is an AIDS-defining malignancy and is confirmed by the identification of both:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HIV infection &mdash; HIV-associated lymphoma is most commonly diagnosed in patients with advanced HIV, a low CD4 count (often",
"      <span class=\"nowrap\">",
"       &lt;100/microL),",
"      </span>",
"      high HIV viral load, and a prior diagnosis of AIDS; NHL is the AIDS-defining condition in less than 5 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma &mdash; A biopsy of involved tissue is required for the diagnosis and classification of NHL. This should be obtained urgently if an aggressive NHL is suspected. Bone marrow biopsy may be a useful diagnostic procedure when obtaining tissue at other sites would result in greater morbidity. The diagnosis of lymphoma is based upon the evaluation of histologic, immunophenotypic, and genetic studies interpreted in the context of the clinical scenario. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Studies on excised tissue'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of AIDS-related lymphoma includes other disorders with a similar presentation. Similar symptoms can also be seen in various opportunistic infections, Hodgkin lymphoma, and Kaposi&rsquo;s sarcoma. (See",
"      <a class=\"local\" href=\"#H8194421\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with AIDS-related NHL are staged using the Ann Arbor staging system with Cotswold modification (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 2",
"      </a>",
"      ), which incorporates information gathered from the history, physical examination, a contrast-enhanced computed tomography scan of the chest, abdomen, and pelvis, ideally combined positron emission tomography scan, and unilateral bone marrow biopsy. Lumbar puncture should be performed at the time of diagnosis to rule out occult CNS spread for all patients with Burkitt",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia",
"      </span>",
"      and for patients with diffuse large B cell lymphoma who have &gt;2 extranodal sites of disease accompanied by elevated LDH, or specific high-risk sites such as paranasal sinuses, testes, epidural space, and bone marrow. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although few patients diagnosed early in the HIV epidemic were cured of their lymphoma, the introduction of highly active antiretroviral therapy (HAART) resulted in a marked improvement in the ability of these patients to tolerate standard chemotherapy regimens and in clinical outcomes that now approach those in the general population. Thus, a diagnosis of AIDS-related NHL should not discourage appropriate procedures for diagnosis, staging, and therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1107590\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Caroline M Behler, MD, MS, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/1\">",
"      Levine AM. AIDS-related malignancies. Curr Opin Oncol 1994; 6:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/2\">",
"      Conant MA. Management of human immunodeficiency virus-associated malignancies. Recent Results Cancer Res 1995; 139:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/3\">",
"      Rabkin CS. Epidemiology of AIDS-related malignancies. Curr Opin Oncol 1994; 6:492.",
"     </a>",
"    </li>",
"    <li>",
"     Levine AM, Pieters AS. Non-AIDS defining cancer. In: of the First National AIDS Malignancy Conference, National Cancer Institute, Bethesda, MD 1997. p.18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/5\">",
"      Akanmu AS. AIDS-associated malignancies. Afr J Med Med Sci 2006; 35 Suppl:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/6\">",
"      G&eacute;rard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/7\">",
"      Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/8\">",
"      Gabarre J, Raphael M, Lepage E, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med 2001; 111:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/9\">",
"      Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/10\">",
"      Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009; 14:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/11\">",
"      Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010; 54:78.",
"     </a>",
"    </li>",
"    <li>",
"     Raphael M, Borisch B, Jaffe ES. Immunodeficiency associated lymphoproliferative disorders. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, et al.  (Eds), IRC Press, Lyon 2001. p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/13\">",
"      International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/14\">",
"      Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/15\">",
"      Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/16\">",
"      Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96:4084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/17\">",
"      Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/18\">",
"      Seaberg EC, Wiley D, Mart&iacute;nez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010; 116:5507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/19\">",
"      Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/20\">",
"      Lascaux AS, Hemery F, Goujard C, et al. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res Hum Retroviruses 2005; 21:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/21\">",
"      Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/22\">",
"      Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/23\">",
"      Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/24\">",
"      Bonnet F, Morlat P, Ch&ecirc;ne G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/25\">",
"      Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/26\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/27\">",
"      Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992; 80:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/28\">",
"      Heise W. GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol 2010; 24:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/29\">",
"      Bissuel F, Leport C, Perronne C, et al. Fever of unknown origin in HIV-infected patients: a critical analysis of a retrospective series of 57 cases. J Intern Med 1994; 236:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/30\">",
"      Miller RF, Hingorami AD, Foley NM. Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Int J STD AIDS 1996; 7:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/31\">",
"      Sepkowitz KA, Telzak EE, Carrow M, Armstrong D. Fever among outpatients with advanced human immunodeficiency virus infection. Arch Intern Med 1993; 153:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/32\">",
"      Abell&aacute;n-Mart&iacute;nez J, Guerra-Vales JM, Fern&aacute;ndez-Cotarelo MJ, Gonz&aacute;lez-Alegre MT. Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in HIV-infected patients after HAART (Highly Active Antiretroviral Therapy). Eur J Intern Med 2009; 20:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/33\">",
"      Heise W, Arast&eacute;h K, Mostertz P, et al. Malignant gastrointestinal lymphomas in patients with AIDS. Digestion 1997; 58:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/34\">",
"      Beck PL, Gill MJ, Sutherland LR. HIV-associated non-Hodgkin's lymphoma of the gastrointestinal tract. Am J Gastroenterol 1996; 91:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/35\">",
"      Imrie KR, Sawka CA, Kutas G, et al. HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-Lymphoma Study Group experience. Leuk Lymphoma 1995; 16:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/36\">",
"      Powitz F, Bogner JR, Sandor P, et al. Gastrointestinal lymphomas in patients with AIDS. Z Gastroenterol 1997; 35:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/37\">",
"      Redvanly RD, Silverstein JE. Intra-abdominal manifestations of AIDS. Radiol Clin North Am 1997; 35:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/38\">",
"      Wu CM, Davis F, Fishman EK. Radiologic evaluation of the acute abdomen in the patient with acquired immunodeficiency syndrome (AIDS): the role of CT scanning. Semin Ultrasound CT MR 1998; 19:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/39\">",
"      Whooley BP, Bernik S, Sarkis AY, Wallack MK. Primary gastrointestinal non-Hodgkin's lymphoma: increasingly AIDS-related. Am Surg 1998; 64:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/40\">",
"      Parente F, Rizzardini G, Cernuschi M, et al. Non-Hodgkin's lymphoma and AIDS: frequency of gastrointestinal involvement in a large Italian series. Scand J Gastroenterol 1993; 28:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/41\">",
"      Klatt EC, Nichols L, Noguchi TT. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982-1993 [corrected]. Arch Pathol Lab Med 1994; 118:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/42\">",
"      White DA. Pulmonary complications of HIV-associated malignancies. Clin Chest Med 1996; 17:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/43\">",
"      Seneviratne L, Espina BM, Nathwani BN, et al. Clinical, immunologic, and pathologic correlates of bone marrow involvement in 291 patients with acquired immunodeficiency syndrome-related lymphoma. Blood 2001; 98:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/44\">",
"      Straus DJ. Human immunodeficiency virus-associated lymphomas. Med Clin North Am 1997; 81:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/45\">",
"      Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003; 17:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/46\">",
"      Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/47\">",
"      Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 2000; 18:3325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/48\">",
"      Lossos A, Siegal T. Numb chin syndrome in cancer patients: etiology, response to treatment, and prognostic significance. Neurology 1992; 42:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/49\">",
"      Lynch JW Jr. AIDS-related non-Hodgkin's lymphoma. Useful techniques for diagnosis. Chest 1996; 110:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/50\">",
"      Eisner MD, Kaplan LD, Herndier B, Stulbarg MS. The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma. Chest 1996; 110:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/51\">",
"      Klein JS, Sandhu J. Interventional procedures in the AIDS patient. Radiol Clin North Am 1997; 35:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/52\">",
"      Bottles K, McPhaul LW, Volberding P. Fine-needle aspiration biopsy of patients with acquired immunodeficiency syndrome (AIDS): experience in an outpatient clinic. Ann Intern Med 1988; 108:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/53\">",
"      Ometto L, Menin C, Masiero S, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997; 90:313.",
"     </a>",
"    </li>",
"    <li>",
"     Levine AM, Pieters AS. Clinical aspects of AIDS-related lymphoma. In: Summaries of the First National AIDS Malignancy Conference, National Cancer Institute, Bethesda, MD, April 28-30, 1997. p.40.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/55\">",
"      Herndier B, McGrath M, Abbey N, et al. A non-lymphoma idiotype is indicative and predictive for B cell malignancies in AIDS. Hybridoma 1993; 12:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/56\">",
"      Schlaifer D, Krajewski S, Galoin S, et al. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection. Am J Pathol 1996; 149:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/57\">",
"      Shiramizu B, McGrath MS. Molecular pathogenesis of AIDS-associated non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1991; 5:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/58\">",
"      Delecluse HJ, Raphael M, Magaud JP, et al. Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. Blood 1993; 82:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/59\">",
"      Balthazar EJ, Noordhoorn M, Megibow AJ, Gordon RB. CT of small-bowel lymphoma in immunocompetent patients and patients with AIDS: comparison of findings. AJR Am J Roentgenol 1997; 168:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/60\">",
"      Lowenthal DA, Straus DJ, Campbell SW, et al. AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 1988; 61:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/61\">",
"      Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991; 68:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/62\">",
"      Polish LB, Cohn DL, Ryder JW, et al. Pulmonary non-Hodgkin's lymphoma in AIDS. Chest 1989; 96:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/63\">",
"      Loureiro C, Gill PS, Meyer PR, et al. Autopsy findings in AIDS-related lymphoma. Cancer 1988; 62:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/64\">",
"      Poelzleitner D, Huebsch P, Mayerhofer S, et al. Primary pulmonary lymphoma in a patient with the acquired immune deficiency syndrome. Thorax 1989; 44:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/65\">",
"      Ray P, Antoine M, Mary-Krause M, et al. AIDS-related primary pulmonary lymphoma. Am J Respir Crit Care Med 1998; 158:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/66\">",
"      Mason AC, M&uuml;ller NL. The role of computed tomography in the diagnosis and management of human immunodeficiency virus (HIV)-related pulmonary diseases. Semin Ultrasound CT MR 1998; 19:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/67\">",
"      Sider L, Horton ES. Pleural effusion as a presentation of AIDS-related lymphoma. Invest Radiol 1989; 24:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/68\">",
"      Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/69\">",
"      Navarro JT, Vall-Llovera F, Mate JL, et al. Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica 2008; 93:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/70\">",
"      Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/71\">",
"      Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68:835.",
"     </a>",
"    </li>",
"    <li>",
"     Rock JP, Cher L, Hochberg FH, et al. Central nervous system lymphomas in AIDS and non-AIDS patients. In: Neurological Surgery, 4th ed, Yomans JR (Ed), WB Saunders, Philadelphia 1995. p.593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/73\">",
"      Biggar RJ, Kirby KA, Atkinson J, et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/74\">",
"      Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/75\">",
"      Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, et al. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/76\">",
"      Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009; 113:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/77\">",
"      Pluda JM, Yarchoan R, Jaffe ES, et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/78\">",
"      Carbone A, Gaidano G, Gloghini A, et al. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol 1999; 108:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/79\">",
"      Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977; 61:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/4/7242/abstract/80\">",
"      Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin's lymphomas. Semin Oncol 1990; 17:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4750 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7242=[""].join("\n");
var outline_f7_4_7242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8194304\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1531008\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201064119\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Liver, lung, and bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Meninges and central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8194370\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201065365\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201065586\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GI tract evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201066293\">",
"      CNS evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8194421\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8194304\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1107590\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/49/25371\" title=\"table 1\">",
"      HIV-associated lymphomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 2\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=related_link\">",
"      Approach to the adult with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24538?source=related_link\">",
"      Fever and rash in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9750?source=related_link\">",
"      Pulmonary manifestations of HIV-associated lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_4_7243="Virologic response to treatment";
var content_f7_4_7243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Virologic response to treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expectation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 week",
"       </td>",
"       <td>",
"        VL decrease by 0.75 to 1 log10 copies/mL",
"       </td>",
"       <td>",
"        Poulis, 2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        4 weeks",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        VL decrease by 1.5 to 2 log10 copies/mL to &lt;5000 copies/mL",
"       </td>",
"       <td>",
"        Ghani, 2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maggiolo, 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-16 weeks",
"       </td>",
"       <td>",
"        &lt;500 copies/mL",
"       </td>",
"       <td>",
"        Demeter, 2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16-24 weeks",
"       </td>",
"       <td>",
"        &lt;50 copies/mL",
"       </td>",
"       <td>",
"        Yeni, 2002",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    VL: viral load.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7243=[""].join("\n");
var outline_f7_4_7243=null;
var title_f7_4_7244="FACT fatigue anemia subscales";
var content_f7_4_7244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The fatigue and anemia subscales of the Functional Assessment of Cancer Therapy (FACT) questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fatigue component for both subscales",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. I feel weary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. I always feel weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. I feel exhausted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. I feel tired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. I'm too tired to eat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. I need to sleep during the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. I need help to carry out daily activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. I feel frustrated because I'm tired and I can't do the things I want to",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. I have to limit my social activities because I feel tired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. I have difficulty in starting to do something",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. I have difficulty in finishing something I have started",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. I feel I don't have any energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. I am unable to carry out normal activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonfatigue component for anemia subscale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. I have trouble walking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. I am dizzy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. I have headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. I am short of breath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. I have chest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. I lack motivation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. I have no interest in sex",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7244=[""].join("\n");
var outline_f7_4_7244=null;
var title_f7_4_7245="Overlooked sources of gluten or potential gluten";
var content_f7_4_7245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overlooked sources of gluten or potential gluten",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        These foods, beverages, ingredients and products contain or may contain gluten, depending on their ingredients or how they are derived. This is not an all-inclusive list.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ales",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beer/lagers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breading",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brewer's yeast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broth/bouillon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown rice syrup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cake frosting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coating mixes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Communion wafers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condiments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Croutons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dates (if rolled in oat flour)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drink mixes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flavored teas and coffees",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flour or cereal products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gravies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imitation bacon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imitation seafood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Licorice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marinades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt, malt flavoring, and malt extract (avoid unless made from a gluten-free grain, such as rice malt, sorghum malt or corn malt; if so, it will be labeled as such)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt vinegar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Matzo/matzoh meal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications (prescription and over the counter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oats (avoid unless pure, uncontaminated, labeled gluten-free oats)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panko (Japanese bread crumbs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Play-Doh&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Processed luncheon meats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rice pilaf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Roux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salad dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sauces/spreads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seasonings (or spice blends)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seasoned chips, nuts, and seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-basting poultry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoke flavoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soup stock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soy sauce (commonly made with both soy and wheat)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stuffing (for poultry)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Not allowed in any form",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheat (einkorn, durum, faro, graham, kamut, semolina, spelt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barley",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt, malt flavoring, malt extract derived from barley",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt vinegar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triticale",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The gluten protein does not pass through the skin. Avoid cross contamination by washing hands after handling and before eating.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Dennis M. Inadvertent gluten exposure. In: Real Life with Celiac Disease: Troubleshooting and Thriving Gluten-Free, Dennis M, Leffer D (Eds), AGA Press, Bethesda, MD 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7245=[""].join("\n");
var outline_f7_4_7245=null;
var title_f7_4_7246="Penile length in newborns";
var content_f7_4_7246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Phallic length in newborns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 384px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stretched phallic length of 63 normal premature and full-term male infants (&bull;). The mean full-term length is 3.5 cm with the 2-standard deviation range, from 2.8 to 4.2 cm. The solid line approximates the mean values, and the broken lines the 2-standard deviation values. Superimposed are data for two small-for-gestational-age infants (&Delta;), seven LGA infants (closed triangles), and four twins (closed boxes), all of which are in the normal range.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Feldman KW, Smith DW. Fetal phallic growth and penile standards for newborn male infants. J Pediatr 1975; 86:395. Copyright &copy; 1975 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7246=[""].join("\n");
var outline_f7_4_7246=null;
var title_f7_4_7247="Prev htn in men women in US";
var content_f7_4_7247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prevalence of hypertension in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 531px; background-image: url(data:image/gif;base64,R0lGODlhswETAsQAAP///wAzmSBzOf8AAICAgAAZTAAAABA5HH8AAEBAQMDAwBAQEDAwMHBwcNDQ0FBQULCwsCAgIKCgoPDw8GBgYJCQkODg4AgcDgAMJj8AAAAmcr8AABhWKgAAAAAAAAAAACH5BAAAAAAALAAAAACzARMCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaaSEgoiEBCnrq81CQQiDQmwt7gqCga8vQ+5aQoKEyIOChbAXw4JCxEJCQ8OyWe8FQAWvLPTXqnbabwRAA3ZIhLP1gAEEhUJFMTeTg4PzwkN8GMGEQYQzQaz4w0eGLDGi4E+Cvea6OtlC4kCAhAjQlSVsIUBaAsWEPAHoBnEiwBATgBZUYmBX0we/0qEKCuFypUwY8qcSbOmzZs4c+q8STHFRQgGGmyclS+ihJANSZZE8sAeFYgpCMjaSbWq1atYr7ZUAXLYUAACCSiQQDRpw6VHKCyg5/QJVBRvX8VFofTrBLUGNCIVoRRtkQS9+jaZW4KwKcN+MyEWsXhU48ReJtSS1wpK48ehMEPeItCAAgoo3Wo7QfglzZ6UNG/OMjDBw7NOLo9mnAGB7du4EWSYPUn16iv7XEOLIrswggHIkysfgIC3JN+/q6jtd9Sy8xGECRxfvrz5JejRp0wQuKCt6Ki8tXPv7lwYsQnHaBh7r0CaOWk67qeAj9+YCAvH6DfCMtWxAF54UUAwi/8FBOB3Hlzpbbcect6VwMsvu1zXAmCq7GLLQ8joAOJ+vIigjzSAKegZCQyqAtgKByL4RATaDGcdesZNmFyFJPQiDEcAsPNAZeqw444JHALgoZIEIAPBPBQcQwAEtVRWSzvSPAQBBQm0MuIE7CSAjggMeIbNQCEZMMFGFXDZSosK6CPWNVxS4GCMMjaxYjqwDaZhOhHqSKFzBjDQDFD/BCVQKwUdhKQBFBBAAUgbjXUSAQ+IVVSZ0tDYQDPp5AWYAQyuCFgDn5LAZgWFPrDkRmvxAqA/EixwkQQWLMAAARlh92eeVUTgzgQMIHQjhDkKyuMIt17Eka4AjPSLSCAxBMD/qNZWyuquR2UIAKJK1mJrqKqM85BnDkD6Hwm7PDDPp6zOUqk4nnn7YpCQSrUnnsAqsZGPxP2ZnYQTLsuXLaOWdfBeewlT37UrvrqivkF5myFQQ5ZJLrmVentCP1PmY4A083bM0b0bRQpRiPz2m4Q5Q0pRnKoEr2dww+QsyibDgkHcIaWeVdCApa5CqgCnQ0Ggz8aVzpsRKwyU0Jk0vCzA2MT1nryPA+kyAIECDeDXsstGSFCgzAIHqiyhDU06y3h5OUVSz0lKrIDSF8In8gJHEZvP0iV7Nq88vPTJqtVgnXS1KibPwg+aEJRZKMu/kg3FPFXMjF3N3N2cEpBgjG35/xASROCwg7GlnayOni/hceiVj94Etj0voTltueW+23exy74EWUYFjCO7PPHu+xXwJS88srCIfrwPEvBytHl+Di9X788fEYFBry1PGvadOJ/9Dp65Vov3Joj/HPjjDyHsruWhXxj7m6jf/g1AVR3ig9/fYv/9NnAAASqwP/6ljzemmQlqekM/AP5AQQREm/UYg4ECWPCCGCwABhpYiP85UAbjqBrqqsc87BQgAChMoQoDUAAOEsKDH4TBSe62gNCkboLpOOEKV9hC48VwCQygiFTkp6r06HCHKexhCdwTrfjMYD5NtE8CRmgDAaEAQMJwUD1csMUS/hAJtWCJLM5mO//VqeqISGQhoRT3uhjUrStN2sGIohIYlNTuBHcE1CYSuJIF2oF2hTPg/AqDRiQqsUfS85iQiLSOdryDBG/8UByf1A4pUalLtHiGnZi0JUx+KUxjChUBRmKAhSlgHmISAZjOsRcBVsZXe5TIMyTixzoYw2FZxMEEyFKBR0KwgP3zYg7TmERCGSoC4ALIotJkEHWVADCRmpQtKhW9TGVqFzTiFAA8BSpYjapULgpKqrBzkXFog1KRAsxRTpWqi0xAV49kjAsZAcNA+A0wCyDGOAy1AGAOUpgEKOQOD8msBEQPMLOAlrT2MhJbWAuQ0wxaodShJI6AC2zMKOW8zFWpdBn/q4AbcUY+kCGSCjygTA1yJkmfsQAq1jMQL/3DLqLGoZFYjVXU+2cwTUhMFBJ0YQnjmUPNoqRcRpJpoxoaRy52kshpFGvn+tF1vvIVkBiqAvFqIzj2VERQxNQPfjMIQpa0JCbBZCs7ZYxAeci2inJEZ2iaW598VtGIKkBoRNtFlJDmD7wxTXArelrkVGW0Mh2lWqYzZ0cWALWQMCBdEYinHj/x1T7cpR8M0NuHSMJHqZiRpz39KcPcFi3yyI2oz4wY0O62kAfoTR98i1aZIgA4qA6uM7D5V17OaYvoOWsWhKtWRG04WU9UFgyfqaUM4pW4lEYNYyq43TBDO88etNEL/8flQ3a9kK6LUDEG0QuiYbe5D4GQUacHJGRP1SiF63Zhu3qArxcecl4Q2opGxShT/KL7WQpm8L8b9KFxq6sGyUwxZsdKq1lrotxHyBcPD75CZz5DXCZI9zAETkSErdCa7iU4vc3LMCI2XIXgKMBGguxqiL0q4jNMRx/19Vd/T0HiMnQ2JrPESYPPALf9fhi9NG7xHQhQwf8CuMhGzmCA3wCgJkrWwjPGcCQCul6frtWQQq4CA34xAWEREZbEs8mOG1FjMlC5yhassk+zTIV9zbWMOCTABQ5A5zrb+QAXYHN89TyHM683zWoWrRoWgA53fVmehTmAABbN6EYL4AB8hv9wpOPg59BeeaCTfsKkGDDeH6sYO4p2tKMhLWBHVJqYgEZzpp1wl7hJEKChFjWjSb3EYRTDiSyw4g2YiIMu+qDMYzh1GlP951W/cMYEiLWsH71Ga5wJe3PEHy9yOgOK/gDYYhC2IS/NVjjUylqeBjOolz3rNYYjhNowRypdCQBXfpKV6o6ZltxkgknlYwRkgUA97jJFEZxy3+mQgAAD7u86OcACXAJ4kRxpIGO3QdsD5bYKBZ0GW7Hl0MVljLJlTese6YMfcqJXQNDEjKNFdl7stFpTCKCPUsWKVCSQ1jIhRltR3Rtj45iWrUrZlYnK4sSSUlejnMnfKUvcympm7xv/fPxqBSeb3IvueEEfkJGveGQjtuiyrUiGLpVeQyr6iCq9UBM9sznzRfYqZVhYzvOoLUwgIUKGBLgk3GjlUdymPjoL9a50NzTAWFOQ7tOhLvWDAUUoHCkKRKozqXCQ63W5YsDcAcs4rgKgTJzmBTHQrjWISYRhe7kXLSpWd9DjkJ56JzZ14UC7N8s4zhsXdeEbtqa3+mMss6imupzG2Mi168SU31gxLsISkpcy7fhy1ZZADxJWRan4EDioUBtu9EDzneJouNIzqP16WEOd2SaoC0cuu1sHrCVUZFlRcG0xKV0Ff16jrwxQaHr8zqejtcxvCNsZa35nDXVhMOJwbABx/zx0fQIIU8gWe6N2gHCAbWFAgBNngHDgAGUSJ6FEQk6ngI02e1PGgGkAcRqAQRiAZAWgAajmgUfATxiFcdkxZ3d2Z3lWamR2ZSGYZCV4gnBgYkMUbogWZgwmg6iXdEKIfT4YE2PGBITWJV7GgxkXZNUnhIHWO6aRYxNxBbpleRgIYtfzhFBYbDLggCywSE2nha4Ahl8AgV24Zl+Igh8YZaVghtjFd0PYQHCIJPRwcUxYh3agh1uAhmlIhMJUYoERSHnIhoDAh0JwY1UII3KYdICoYKYmMFORFZRYiZZ4iTaBVnYwhZM4J4yYhl4YA4hIAvKAhyk2AoqIiaq4iqyoY/9+cCB+2IWPSIZYIDmEeIpfZIX0E4tQOItABhzRAwCRgnG5+BS72IhRuIZc4BmJ5XpJMIrFiHctwItzqIxbQCP2VmFwFo1aAIvIqGrWqAVcMx6ulQSdpYncaAXeCIqrJ4qGCAO2lhI49o7pSH0wQI2OOBqpKEud+INLAE2vxIT1iItR8Y2hmA4u+IIwmJAKaWcx+DuSEwEXCGUD6RA4QYViNl3siGXj9n2PpoGyR4/LcHdHAI3HQwC1kTu6k5IqmRu7g4/JqHEe+ZEzCX4QWTUTuY0VWQTqISgUwjkFIy8G2Y7pAJIbaJQbaIgAGXj0mIs96ZO24ZM7IpQbOWyjMXj/30dnNcmBRRCPTLmTRvCUygKUNkOVVYlpHZmVSFluTGBglEGMYLkDYsk6ZNk5ZnmWE3eVa0mTM8mVRDBhoAGXcZkDc1kwdckeGomXaiiTHqmVfWmIHbaDBDmYOlCYNnOYyuEdMAmOjKmWWwmZ+nZi2th9lAkEltk5mDmViamYh4SVhLeXNqkEL2YAMfaMTflFp9kdqTkoq4mXrbmXjtmYhthj3EeapflruxmVUskcd6mYfeea5BacWWmIXJM5t/lDuZmZu8mcvXmWv9mXsOmXQ/AM1nmcpkmWG4AbGcCSCLABrNOcrKmXy8YBDsmQHBCdhjhYxmie14aeLWkb7hmU/91Zld8pa/TZkAdwn8smnkLQeoLJn1+4ncvJm5t5kNBZk4RniNrnazcELKl4hM8ooROqmUOJg52JodM5CCa5CJxIS5kjostJos5ZTGmJohnKBBToag+6GtCYnROKmBVKlBdqoyHJBPqQACi1o5vRozAqlTI6o88JmxjKoEGwDyKAOQIZHkz6oyMKn74pn0R6o7ZTHZKipJCxpVzqpF7qnWAapguqlINIkkSwog52nVHRpFC5pgTapm5apEuwods3mVpqp3CBp2szoBtZoH3qpwgoO2iapocapCZalIvKcYSapdHxqJAqoJJqlTVaqVF3qYKaqaK6OptalojKjooKqv+hqqKlWgmaeqpAWqKeeqKsSqVAACbBg6m/EauyqpqdypG2Cqq4+gMOyqs8+qqb86uoGqxoOayVWqw+UCinY6aJ4avM+qQzuqq3aoi7Up6jg62/qq3Oya3EqqE0snjW6hfiKqvkGp+feq5McKw6YAz780sB6KjKyhiG+p6pCormGq3UiUvfJR+2og37lBH+9GlosY8RgZH+iAQ+Cqnv+qXxKrBNIEARtAOS8zZ5gS/F2YQlQWQ2KIIkWLJLJrH9yqm0KqyUyqps+Tu90FKVWR5L1XMNcY77qqKpJ4Ehyqx2+a9/yKfdioTKt2U5kC4qMgtkxVnzeKY9m4/+srLN2rL/z/qyMBubSeBmhDmIzvUtinN6FRGLqjepJUm1Qeus3QatiyqtPWAQBPApIfsCWDQpFIAMH2deRXetURuTKgu0swqlUZq1rboE/VcoT2YDX9Fu+jW3dPoHZOuzfwu4wGq1a4u1MOu2PvAwY7gUkSu1P0u5FGq5eXmxbYuCw3BLuYSswPC5fnu2oju6ghuwp2sSwAduozoNrsuZLnEa1Ya2gQultNunmkuYFgA86sq6ubC7B4kCLRoRIJo+wJuZepqoRCuvhisNFVCbtgm11ge6LuA8E5umFcumpku83op4Vqq8uMC8RDmNGTa+XFq+e3q+blq8OlA+Wzaa3cu33/u6//aouNNbubN7vRi7BPsQFJLZoaHwodPYt7wLvzggvz9Kv9Zrv2GKvznQGRJgaOwrCc+7iJ+IZpIrwTdAwV0qtLJowLW7BBbQFBOASR9sCTHivmYbwDWAwjFavarKwuibsdU6w7BKhxDcvDhMAzqspirciz58vxoaGM4osTvrBjVMgyaLQSZYq+EbvwMsu8LbxBkMmRqRvLlbP0ScRjWYZFnssiYswLHLnWpbumz7w0uAX/vphKJIujT6AuLbxXCsx4uJuUX7p66xumWsCVVcwPfIxW9swT2MwUSqwb0GxetKw2f8xYs8wX7syAALxpFsiMhrbYesGJe8rUx7kf3ou/+ksck83MmQbKOSrEvD4JUMbAkOK0Y5IUSAzF5yhqD16csOqSFJnKdLXI1z7MRM4FvTU8mGgJL/qZ7s+cy7U8xSO6SyF57CzMrU7LfWTMdKsD2ms8BZCKvJuZ0VEsc02s1H+ZmF2sitPLSvjKKxbAPls4JC3EHlnMLbDI7qPGvY3M6xy8nwfMxhbKQUAD9zG5ZTjF35vMNqpcj9HHX/vMruvM8WKqXsvAT5kxcLa5zkHKPmrA3orIYRzZfCCdCiK9ArHM9T+o4a29EenRoNrcQWvXolLZ1iKr0VPdKDS7jzXAMNUB0VcJ2P24czTcw1jYM3PdE6HdDvvNIE/clKAB//xSIMWDrKGnbUh5rUnrrUGd3UKf3UTMzSX30EuzCIgFfLH+2kIf3QmOzVj4nSlKvSYx3VsIyCDOIMENFLzIzPIK3PPN1DcH3SFO3UXO2yJS3PoByQff1CWu2vh42W1nygdHYB9omfcg24dG3Mgoy9SkCed/wdjy2gkd1tk+3LCmqpmQ20mw2+id3STKCfX4kJp5met7GeuBGgqFrapfvaZU0zO73Lw4vM/0jJ9+zYE2LbLanbQcvb6YzRcV3YYe3cgezb0a0EG5rQPLnQ76XN1M3L0E3YYD3XYs3Z1i3eh8jdXDDMWx3Y8hLeKSrd5P3dw13QhluBEtnYKurd7t3Z/wc83ppd3q4N3zmdBCp4PhZ5Vupt1BVN3+9NuFoL3Ibd33at2Eygg1H8AzqrGPwt3A/u09kc3Ipc4bC9BEmoNGk9zu2lyk/R4RBN4Jgt3wHu4GR93c8YGNE7BHwYwp7Y4g3e3+cd3wDO2gLOzTD+pk0ghvq93Qxu2DQe5AUu4dNN4f7dwkvAH7PdjVPM3pAN5Eeu2jJO5DRO4r99BL6FuEs+p1vu4m/95YxqqjNO5VAe40rgEeOQ4hTZh2v+4x5e5d4M52Iu526+gEhIEQiO1TqJBVxO2l4O4Vy56FU74n5O3P4yNBTGuSqujnvu5I0O4qudrUXOu3OO5MU9iBmu5v/rvenT/eSDnpSfPq6hftGODsowwb1MrudNvuqdnrWPrs2CPuspkbhqrYu5Pt+sDuxhDupjPun2/dkLsEmd+wIOLJeqbuy7nrkhPuF9TuY2jgQSEJF8jej+xo8uygK3LBWprEArMO0RyucvjuxDruy/7ulNoAA7Bzp5fsJ0eLJJNoIlK4KVw+M5DujKfuz0Hu+wvuyjDuZK8O3gQAHOIO60+MD/G8FHjMRsbsrMLtXJnvDzzutwSgGvVLAlKWKJTMLg28ZuzOl9vvBvLuXz/fHYHuzg6ryonMtu/WclfPG/6+5tDu8E7/HbvvF3rQR8ZOsKHV3R3JK4/cy3LdJF/L7/PN/uLP/uBx/07hrrQtrqMSuxcXrqt/7qugnYUX/D+arJPq/xLk/oHZ/1Cs/1hZvgtEXGww7zdEn2FW/EZ3/CGV+uHw7yYn+qrW3kQJ8EoB3tdp8cyq0b7MnciKnCZeup5w6xLI7wbm/wgN/2gq/1k7r2rj6vYF/y0eWf/+n41JvzllbNDImglg3MdfaQmr+p59zycB/hy6rtku75XV+SX0+MkN7cNtzVwMnUlr/5qA+vuh/3WG/8Mj/IXm/qvt/3KpTGGkSCayzZw1/mt6/rtF/42x/zQ5/8tt8Hj/H7jw+CJXv9pp393Z74BX/tzr/8ss/5Wiz+P70G5S/9FjvY/0IOAoA4Eshwoqm6sgNCiEQR0LV943lQwMQhAIPCIbEoOMBGylKr6Ty9ADIdtUrjkX7GLfeYVILD4jG5bD6jz4SvmPl8q6LSmbV+w/q6wINWjyS7wQnKTdkZ7vT06S16jQUKvkUVHtZhxSgydv2lcXZ6fn6ulT1COhHSUVrhYQZx8PFdXLwecGxttpmURiZNplKtZjLegpHqskii+upYSrEGFw2DSk9To4kC5ho3nSpXARe5zorXGkUvZWsf8yZ33yU++7Gdp2/3sLfXMOfBc5lX/wOcds0ROnopuOHD8Y1fOXnzDK5AmNDGQoZE/EkpCNGFvYnuslhsGHAkyVAOH/9uRCHRI6JmIaGdjKER4kqPFV/uiVmMZkeWV77swxkEY8miRqXElJny4DqfP10KHZp0p8GaE2/ixEiVHjKnLS9FlXp0LNmBuJaqbOoU60uiW9NZTcg2pNaZVXv61OeMblKyfsFMkEBAwgQzZsO81RYX31yLbu1yVZv3XdhGZ9FynONVb2XLfz+PYWAggQEGhvsmNra4XWOGjzFn1ryWcti6sLvOBlmZKGi/EAw8APDAAIRRqCHDlcyyNb/XmFd3Yw7P9nO8y4Huddy391gCBnp8F6FgDfk1CRKUT08gQQYE7t/Djy9/PoIM6NdjKKB/P//+/v8XgAF6CcgijoEHIgj/y33qrdcefQ9CWN99CeQHoIUXBjhggQlyiOAFC6bHXoQjymcffhii6J+A5BHYoYsGXrAdd0Z5B14S4zGYo4478tijjz8CGaSQQxJZpJFHIpmkkkvyqMCMM1ZgQAMANGBABU9imaWWW3LZpZdfpmGBAREoEIEBFoCZppprstmmm2BKYGYEErxZp5134pmnnnvy2aeffwIaqKCDElqooYcimqiiizLaqKOPQhqppJNSWqmll2Kaqaabctqpp5+CGqqoo5JaqqmnoprqoGiOYUEFg4ngKgHFqXqoAg4oAcEarILhwKuEjaArsIs6oACvulbAqxIKMMtssIMV5mhpyYIh/4EBCyQQnAULLCDalLUO6oB3CYxAQWkLGOAkGAawO5oI5opmmqIOoJtElQxwq6wI7bL7bmmlPepAA2YyQK2YEURLpZUAoJswuH+S5u6+BkxQYxh0imkAAA4AbC6diYoW3gTXAhDlt0qw2+zGHRvw8aNxhhclvguT5mTNDwuqgMQAmBsBAww4PIICVcKgs2kWI0rAAkQDoDO5TofBbrZOGi1FeI0KTDC13lEAAboW3HwzzoBCLYLM1xbbbhISkPYtwWbKyCfHuoYHtdM6swvDAwSYuwCab1/N6LTKRglDzcMVJxquY/9ZNsfkRpnABM0qe7OrFQynrqHe8UsAx6b99v/A5MxWni4Al2fuqATNkn76mF4vEBhwv0XA+J++lqbABGIuAIG5FIChAAMEVHkmABCMBzCiFjD7+9/EDeeyeMP3XRjy3snbKL95iwBzBIs3gC4Di9vOZ8QpAwDzAhQEbUHIEdBK2vpBH4q0A6ItHYb77I4vgvzsly+AAhwgAQtowAMiMIEKXCADG+jAB0IwghKcIAUraMELYjCCo8sgBytYPFp1MIQONJMBgCcCCCSAAtdQwAMS0AD6AaBiGJvV6SiQQlyx8DxXkoIExLUxGz5AeiIcIqF+U4GGHa80BDBTEh9QpeCIIQILKFnLtjU8bklBhaSh07XYJSbqQZGIYhT/lLks4DEAkAZNpBHOd5aosTYQB19U1GK6JoA50cBAeRyLQAMqAMMxAhJPIxsNwdD4xjWSpjyt+teUuEYe9y2gAoUDwM5QKL5AYnJPUVKhGwX2HQgwMUoPUIDvqKg5/7ELV59DXgP2OLTwSEwBXVMAFjNpSzuJJlpVeiFpIsBEKZAwOA+oXbWUd7yQMcAC1hoNLMl1OmSS75bSxJMyFSCBbo1hAUJU2Dan6U1ioQs40RyBBcKoBG798ZvqXCc72+nOd8IznvKcJz3rac974jOf+twnP/vpz38CNKACJQmO1HPKgSL0SQUtD3oS6tAvHeahEp1RRCd6z9WdEIRbqqhF/+vZUCo5k0sc7Wg88cYvc2pppCR9pwMSsIAInOcB48ySSlf6ToymqaY2bacDWniek200bjtVJwml5iWdDlWdwFETUpPqTScyVahOlSYFsPXTo0p1qrY8386CqtWvSqOpYMXkBBqQgJ5qNKVZHesYh5MuCqCUpmtlKxGtlIDxhNSrdGUnce6aLazulZ1VfWnLABtYdU5gOPkz7GG9qavTeY6xjZVmBJLw1y6JdbJZWqhBK2U6KeRVrZp900LPU56DQioC7JsAA0wo0rmOVq6a4hz6MAvb2D4ps4ti2wPSKlrc1km3iZJAN/UKXDcJF1EtjOpx35TcQ8WpWTPF0nOb+/+Z6haKq6GVrXXZhF1CCYY8xaXobbvrl+8SanLqlax5/cJZHZn2R6gFb8oYANTftvcvBKgQhjDA3/6Wt04+I9N62Jvfo/TiF/dYRoDflK67mjUggSGAH59FLeMcWL8LVsiGFdJgN6n2iveVBmuZGTuF4ctvGM5wWTpMERdT5MNt+g27VPyPqtVsZFM02YpZjGAYXwHIT5kXhfU1jRIzQLVNc1fZ3rseGfvYEULWjyGYgShkGZnEVSXY5JgcSwZ9FJDFKszkWOWsTSV4GUL+CqKKhzaATHI4ngNY6Ho8RqZZKzhVQ/OU12xlQwGHlAuIKyisxQDhFdZMEIiencX4G3L/9c1qUyrrDbs3KxdOwIaLy+EL0zerB8i0T2nOAZXt8OdCHToG25VG+MaUhPtda8TEgPICSdYtA7TUdPgiAL7UOCYzYWtMTXyiIX0mbD6NmsNVprWazGoe9IwXNOht4BaJYyV0rWxKRjTkkg2nMTm7kdsAEI2oN6wB/viXPxr4BbPTxFWjGheQUWJikpeqs6KFZ4335nYiySPuNSLb3BdaN4PR4GTyzLdLxWLdrV6bSY4tlXM7fCkLcc3tfa9RlKQEHsABvqdksyZupQVRwkE17Qai60oQXxys54TKbovbjUvt+Bs/vuZDnFoN7YbUyaOMmJsv2yQP6/lhD76GkpMA/+imnivRI9X0vY78tGpQeiWYvvOxyBLpvXn6ZHUL8uhYPU8QP6vDfX4aT3xdGTk/u57GE+3rXr2xXqe6KsJeJ0qj1cBmnzXa6e4Nu7/JrbIkdG7jfti5bwbwbrIrXvW+dxKsNe2+WHuj2dRXBVy27I9vQ+T9zm6h12mwZnq7tA0fWMTnBu2ml7BiZU3d1dMV9ZMB/ZuYF0PdOb65Rg8RiJokm9mL50fx9ZHWx8KA4ExAybZlMQEcFKEMOP/51rEJUDbEoVi86AAxytJnC7z8DKfGBchhyu+voxtNZGcIvCFLJEUA6twfN/zuGcT0r4KdRfBBGLAfA7xEQ3q4M9/4Qf+BAEJB/cnF/flB+gnB+o1FpsUaRO2fRMkfAWaG5KUCZySg/nUK19nUBNJf+VHf+fWDAooFllxTu6xa4QUgHMwfCxogYyAg+mkglqDLebgQ/AGXB7ogCNqfCNoCCeZEliwWmHDgSungLvDgAfpgOQChZ8xIA7gWBK4gC2wAfEAffGxAPSQhDC4hNDQhAx6FduEgblFFFT5IFrYAbgAfVMgg/kVgGJiVDboeeU0hWqih+YFFBrrhBr6hQ4VfKdxhCOZhG8ZDlsBameyQ5n3T7hUfRVEgJARiDw7iCM7gk6TY0KQgHa5T1CEcUz3iB1ogJWAgIWpCH6IMCjXe971TEQL/xB9C4guGXBdexBea4ghEUgKAUhR+hpOFmTux4j+4Iih6XsFNohCEAyxYHznABE3xSyMSFJjVYgL9YjUE4w6GIs7F4BAc44Eo40VEo9lki29x1yp+YxpUIxJeY9AVY1aU45pM4wO9o0B8ojUOI6llo1CAYUnY4D7OIXfEYwP9Iyic4xNEohKuY1vU4vbAmyK2U0CGwjyiYz16mCxqBx/Gk0OiHUQSJCyCHUW6xjf2lByO4S1hZCcMpClwpNrdIztmScgsZLw1ZDuqgUai5BbG4kHyBfdZC8/IZAz05ACVJCecpBam49J5ZHN8Y7qQSYSpoi/+JDbcRkpO3koiZJZU/5a5LFVTxqRz0SRRSuRH4GRFYokDOEBiic5I2lJQmmNXpqFUXiBV5iSW4F5OPWUAqaU1sKU62GRHhuVHZglpdA0R1mX53OVMRuVequRRTsc3SsD7JCJMslNhGkZeRoRbiiJciqUhkkYm+uNgisruMVTv7YgzksRQtiViTqViPkM+FkVj1thj4tcY7VeKpBtt1qJp6mVRVp1qBgNr6mMJieM4ymafqaM/UmYcWCY28mYm+CZBpZNwipEFltpuOuJh6mbdLWclzgje9RZaWpB0+tltHif5XeffZeceYongwZV3VhB4FufWjWdaoOZbnmchYgnjeR9DEpF7GmV1Vsd8Xv9mfZYi96Fi5kHmEPEndRqndX5ljAloP3yj6BWWVu4ncfbngv5neX5eXyJlliTWA7InBSUodvqnHSZncQZFVDTnSJAlcwXSiJpniS5FQXIhhy7mX3Lm62ESjG4ohpoogCqnja7mN0JA9kjhi1qogsIngybeg9rCN4ohhSJokpKoj87oiV5oiuLjN8bhVUmpCPEoMVppStDoTbKhinrmgYIplcbomG5EmfLlmW6pIeJPP3bmjgrcftSmfhCcPeZWfBYgkKJoEzLnN5pJAuBRiE5Qsp2bhfTpRMoomWKpgmopS94nrSzXl4aQhorpkmZog+YDZvoldX0M3yiqBHGqn0b/6ptOapVWalViybt1lY4iaZOuKk8IapYSqnZyR5eKJEAUy7EUGdsBUqpCqpviqrGCpZxaaqHQy9XcS75U3pTaKrLeRa5S6q6iJ6pxj45RUT9Kpqkoq4Pe6rWOa6g6qUgUitIwjd18mXr0YnSC6pBZa2Rgq6tqq32GC3FYjLs6Ey+mqcnNK5t56o+eK72+alw+iR2JVytuz5yBTlY6QsB+ysESrLQBagUO7Cii6V/yS46GSfOU0PMs2oROLJ5Wa8Fe6b22acJm5ozkDrNMl0BcDawN4cnWauqRASMKZMbCaWIKaW9+4/C4aLFu7HZw4tH1LJPqrMuO6pMMTMNqagdZ/yzlcR4w+myrtmy+DmisfuypRlDVZhV64WZlsmyPOm2HjiXrzKwmGm3K6hzWMu0apu2NGuKwgi0Eia1JfljZIufZimndDmmWLNObTS0H7a1Q9m3WAq6qMiusPsmgkdLx5S08Hi3fyu2nVqvgCi33qUt+qummXq7iZq7Bju7jKuyMJBnx3GxsyivcEqs8zi0eou7LcsezlsZzbh3FekrimuPizq4g1u7TymXbqmDOrqE1AK/mNi3XQqhCTcDCyWzlngrPTh3sTmtGBq8kDq/acseDfe3hlk/SEkAj+q7ylu7K+i7nFmpuKVN5/J9+8W6iCNf5xi01Mu76Ou+TGiKuVP9A/Mqv3jLd6aIv/m6vQXav3VpiA3BOcLotQA4w9gLC8pru5u6vuj7Jgx0f4T0wA9Xv5YImi4imjiSc35Ln6bIvr/aGtTEwyAIgPEZwbhCA9SUI9r3I9l1GBTdvZ6xoQLiVBLyf+BLQBzep4ObfthJD/qLwBS8jlpQTLznwncJwKFyuEdMiQRxwjSbw4BqidFFvrRCxDAPhEetrEmexmaYwEvdq+OqnAoXx7FmxCisF89ItE3sj9y2A1LYxuITwswHJ51bxGF9xDqvvEvOwoXpmuApK85HIFTaycoRgHKsxCSixBR9ylpiVFwuxuBJgCyJh406kJJcxShSyJe8GlLL/ceiqyhFuZAwEMv4NMmJU8g6fMuHC7xejWSdTIHQkpih3rSyfcZym8Shzh3rN5R6DsS5/ICh/hC8/LyFLKjOT6xZ3rgnWl52Wnl0q8w5KM7o6M/9CM6t2M8LasfoZapKlIjKv8jZ/8t5+MwabMR3T7jD/MsxiHibi8myxcyuPc0u8cxMDszwLLz0/85OEGLvmc6awck32s3QcQSzHsw7X8SVjCY1dS5Ydr+2UoRVGHxrqZUPTBiVO8hxL9DyX8wKWo7hcGHcArDa3gBnSh0ebLUij7jbaMB90ozljsUBzL0GDM9R+zKvMSEsTJuPSdMJuo4HkNErvdEkP9EmXYDEL/w8FMEumqnOqmLB8HjVUB2E4J6sh1/JQK6QuQifOZHWgbjVFB7RT9zRXOyFoWMAS3UeFbXKpnHVsuLNbUwdbI7BPwzN3SEAU06pGG3Veq3VElzIt1waUurAUE/ZhpnVYr3ViT7Rkz0iRFi3j3DUvp6ZfAzRiR7P+HjZ3ROlVo8pmQ3IPevYde7W5gvViYzI/JjSmoLYrF7Fe68QsVzZsc4oiB0ptRzZvT3Zov3bHjqVoIOJsXwpwG7ZlkzJxm7Jwqy634HNdkwpzv7JzU3IwAy01t++l3hXouq5ZF3Z2S/dzi7Noazdo3GIuKrelYPdtj/Z283Rf4zYztgtplsX85v9JfIvxfJM0ZZs0gINGBYTjkT72fwa3cQ93ehf3nHpowyG4Zpe3fK93RnB3agbtdz9J4QLNe1eKf8Pxfbe2var3effGSxFPCYE4pYi4+a22Tpd4ctD0hsvxZyyAujClaZ/Ki0cyiTf4V0c3g1NUAzTPKBnvC6uJ9eZUhf/3hdf2iRM5aStkY3dHwJKvfmMsZDc3igc4dCv2lPdGeN2yKk+4dzn5iBN4lD94sw617mY0cvG3j6s2kIO2gw85hD+JS1FAkju2nAdXmsO4naO3kIe5ns+Ia44JXZt5i48EnSthjDP1jCuG1qItoQ91OAVOWacBk5dBH6/HCOeIlgcEpHP/oaRH9Z0b+m6LOWgoumrBFI+LQZZbw39ZyJ4CGHUJ+o+vuW4P+IX/BWCCkJ+fl4y9sTeEp65zuXm3OobXtxajeldDb2YLRAyrQrJ/+miG1a7Xea9nOH3a+Ei7l3oA8H63orXfQKPqB64/6rKOAa0vrYJ3ebOzeZ67ubRVOfyB+vD1CCDrgLr/R7tPcwEbsLwzO6IXumvbO+T2Bo740hqU+5WPQvQ9iCOPSAakthLuu6gzSMmZeixG+1vTN19DO6b3xnnQ5SjsM0O7Mw17iMt7yFRwe6SbvLOTPBrX/GegvGCqPAvucsafuiDfuM2v7IIj/MgL+FMTeFnk+9Ru9HtY/zwCyPTfGn0rzMJN08JPB/m1Vj3DJ7yJt7nXX1fTG8WEDcsE9zwVQsjUk1/XC0BSj4PWqzrXz/vRfzmeH/q9I4pokIaRXi1UGryFe/nd46rb2y7Sgzmr232h1BniZC/h0/3B6z3ii7PhE+/X07iULz6hWAzS8CLHNwiJiL57mMiJpMjpZ8h6wHz2eQjHi8joN/KE2Drq37qGsH72fUiOvD7sP9+AzD7t/8eKmMfq37444LCidP7VgDqTMH/zO//zQ3/0S//0Uz/xMQqPVQlsbt4/HUyZGM/2D5T3RDz4k3/5m//5o3/6q//6s3/7u/8FSfgJ7YoY+Aq0PMvZJ0qwWv9YljEcCAAiREiTiKbqyrbuC8et5VpVKdoEJPf+DwwKh8SizEEwJFAUA2NhUKwMVKWoyXAat1yXA0oQNZyLBU1VpV6d2q77jXJWziiJYZF4ACzlbAMOGCg4KJhAtSRCNZEUpiKxp+ag1fRIaPmSZRA2cQdQYfCHFqUgJckAQHmpCuPQECFHY2EQcSJmUAEAVbvK2+vrpmC1FsHAsJuiMBYWfMr4q0qwoAwQvFQ9pfQgxQzg/Pws8Rr2+XQLYCiF/r3O3q5yLUJ+5xBM1ShhGPrKIO4OKElCEzUr1eoJfECgiRkA+/r5I9Rq35xuBihAgGJBnbqHHDsOgidpyacEE0j/KaBzLsqeChUeqPS4JUkaAqYAQDDwoCQplOpstHwJ8w2sFJ/CoHPJI4uDoEybBnFATsEEWQsgNKHwjgGBMQZoQFCQ5JTTIRZIXaXxCoLLSigUaFV44mvYsV0kmNwJKcLFBRPsPLgZga7gwSkMVZES7g6FY3sy6RVhaMFiwkK8OcgibYWFTAyWppTMmPKPNPZEJI7guQGUzqJbu34NO7bs2bRr276NO7fu3bx7+/4NPLjw4cSLGz+OPLny5cybO38OPbr06dSrW7+OPbv27dy7e/8OPrz48eTLmz+PPr369exl62wPPz4vrjzk27//5lVFFBASUCDQiAIPJNBAaAAs//KIBTvsQYF/SwmYQAK4dCMBEgA40OADbOHHIXQ3VaCLTU4Q8IqID4yhBwsRLOCJARLwoVUZ3fxnyCN3UCHLWyl2yGNzTViQiiE0GAKASwCWyEISEDzRIo1RTNBSFmG0IUkEDVRgYI9aDseJEvukBJkBKQEI4Axs/JHEfwButgBLAgljUwKrbUmncZ+o+UormkBQ4ifaWNWiFIVRsZQpXzVQZTJvIqKARQrIWGekwWVRyxgFGhIBkiRSoccDgTnShk2cWWCHEovmwJlnkq5KHKkKSLCAWCsssKEttbKK63VfcKpqChbsmEIZWeZKbLHGHotsssouy2yzzj4LbbTSTi9LbbXWXottttpuy2233n4Lbrjijktuueaei2666q7LbrvuvgtvvPLOS2+99oIbAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of hypertension in men (upper graph) and women (lower graph) according to age and race/ethnicity in the United States from the NHANES survey. Hypertension occurs earlier and more frequently in non-Hispanic blacks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Egan BM, Zhao Y, Axon RN. JAMA 2010; 303:2043.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_4_7247=[""].join("\n");
var outline_f7_4_7247=null;
 